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ABSTRACT 
 
 
 PTEN (Phosphatase and Tensin homolog deleted on chromosome 10) is a tumor 
suppressor gene that is commonly mutated in multiple types of human cancers including 
endometrial, prostate, breast cancers and glioblastoma multiforme (GBM). PTEN 
functions as a phospholipid phosphatase antagonizing phosphorylation by 
phosphatidylinositol-3-OH kinases (PI3Ks) and thus serves as a major negative regulator 
of the PI3K pathway. Homozygous Pten knock-out mice die during embryogenesis. 
Conditional Pten knock-out in the nervous system showed that Pten negatively regulates 
self-renewal and proliferation of neural stem cells, negatively controls neuronal size, is 
required for proper neuronal positioning and is involved in the development and 
maintenance of normal function for oligodendrocytes and astrocytes.  
 
 Neuronal precursors (neuroblasts) are generated every day throughout life in the 
subventricular zone (SVZ) and migrate through the rostral migratory stream (RMS) to the 
olfactory bulb where they differentiate into mature interneurons. The signaling pathways 
instructing when and where these tangentially migrating neuroblasts stop are largely 
unknown. In this study, we found that the PI3K-Akt-mTorc1 pathway is selectively 
inactivated in the migrating neuroblasts in the wild-type subventricular zone and rostral 
migratory stream and activated when they reach the olfactory bulb. Postnatal deletion of 
Pten in the SVZ resulted in aberrant activation of the PI3K-Akt-mTorc1 pathway and 
enlarged SVZ and RMS. This was caused by premature termination of migration and 
differentiation of neuroblasts, and could be rescued by inhibition of mTorc1. Although 
this is consistent with previous studies in lower organisms showing that Pten was 
required for directional migration, live imaging of acute brain slices showed that the 
migrating Pten-deficient neuroblasts were not defective in speed and showed appropriate 
directional movement. Therefore, the apparent “migration defect” in Pten-deficient 
neurons was secondary to ectopic differentiation rather than an intrinsic defect in 
directional migration. 
 
 Inactivation of Pten in the neural stem/progenitor cells at birth also revealed a 
novel perivascular proliferative niche in the cerebellum without full-blown tumor 
formation. Co-deletion of Pten and Trp53, two commonly mutated tumor suppressor 
genes in human brain tumors, could synergize in generating high-penetrant 
medulloblastoma with a growth pattern centering around blood vessels and extensive 
neuronal differentiation. The Pten and Trp53 double knock-out medulloblastomas 
spontaneously lost chromosome 7, 13 and 16 and had mutations in the gene Ptch1. 
Therefore the PI3K and Shh pathways cooperate in generating medulloblastomas.  
 
 Our results show Pten is required for appropriate positioning of neuronal 
differentiation and preventing ectopic neural stem/progenitor proliferation and 
medulloblastoma genesis. 
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CHAPTER 1.    GENERAL INTRODUCTION 
 
 
PTEN and its Signaling Pathway 
 
 
Identification of PTEN 
 
PTEN (Phosphatase and Tensin homolog deleted on chromosome 10) also known 
as MMAC (mutated in multiple advanced cancers) or TEP1 (transforming growth factor 
β-regulated and epithelial cell enriched phosphatase 1) was originally identified in 1997 
as a putative tumor suppressor gene on chromosome 10q23.3, a genomic region 
commonly deleted in several types of human cancers including endometrial, prostate, 
breast cancers and glioblastoma multiforme (GBM) (Li and Sun 1997; Li et al. 1997; 
Steck et al. 1997). 
 
 
PTEN functions as a phosphatase 
 
The structure of PTEN protein organizes into four functional domains: N-terminal 
phosphatidylinositol-4,5-bisphosphate (PIP2)-binding domain (PBD), a phosphatase 
domain, a C2 domain for membrane recruitment and a C-terminus containing two PEST 
sequences for proteolytic degradation and a PDZ-binding motif for protein-protein 
interaction (Figure 1-1A), (Georgescu et al. 1999; Lee et al. 1999; Georgescu et al. 2000; 
Vazquez et al. 2001; Das et al. 2003). As indicated in its structure, PTEN shares sequence 
homology with the family of protein-tyrosine phosphatases and can dephosphorylate 
serine, threonine, and tyrosine residues on peptide substrates in vitro (Myers et al. 1997). 
However, no protein substrate has been convincingly identified in vivo so far and the best 
characterized function of PTEN is associated with its lipid phosphatase activity with 
which PTEN catalyzes dephosphorylation of phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) at position 3 on the inositol ring to generate PIP2 (Maehama and Dixon 1998). 
This lipid phosphatase activity is direct antagonism to that of phosphatidylinositol-3-OH 
kinases (PI3Ks) which phosphorylates PIP2 to PIP3 and activate downstream pathway 
(Figure 1-1B). 
 
 
PTEN negatively regulates PI3K/AKT/mTOR pathway 
 
PI3Ks are an evolutionarily conserved family of lipid kinases that phosphorylate 
the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides, the crucial 
regulators of a variety of cellular processes (Engelman et al. 2006). PIP2, one kind of 
substrates for PI3Ks, is phosphorylated in response to activation of receptor tyrosine 
kinases (RTKs) or G-protein coupled receptors on the plasma membrane creating PIP3 
(Engelman et al. 2006). PIP3 acts as a second messenger recruiting the serine/threonine 
kinase AKT to the membrane via its pleckstrin homology (PH) domain. AKT is 
phosphorylated at threonine 308 by another serine/threonine phosphoinositide-dependent 
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Figure 1-1. Schematic PTEN secondary protein structure and biochemical 
function. 
(A) The structure of PTEN protein organizes into four functional domains: N-terminal 
PIP2-binding domain (PBD), a phosphatase domain, a C2 domain for membrane 
recruitment, and a C-terminus containing two PEST sequences for proteolytic 
degradation and a PDZ-binding motif for protein-protein interaction. (B) PTEN functions 
as a phosphatase which dephosphorylates membrane-bound phospholipid PIP3 at 
position 3 on the inositol ring to generate PIP2. This dephosphorylation is a reverse 
reaction to the phosphorylation by PI3K downstream RTK activation. Modified with 
permission. Chalhoub, N. and Baker, S.J. 2009. PTEN and the PI3-kinase pathway in 
cancer. Annu Rev Pathol 4: 127-150. Courtesy of Dr. Suzanne Baker.  
 
 
  
3 
 
kinase 1 (PDK1) recruited by binding to PIP3 as well (Alessi et al. 1997). To be fully 
activated, AKT needs also to be phosphorylated at serine 473 by the mammalian target of 
rapamycin complex 2 (mTORC2) (Sarbassov et al. 2005). By converting PIP3 back to 
PIP2, PTEN antagonizes PI3K activity, limits and ultimately terminates PI3K-AKT 
signaling in cells and this lipid phosphatase ability has been shown to be essential for 
PTEN tumor suppressor function (Sansal and Sellers 2004) (Figure 1-2). 
 
Activated AKT is able to phosphorylate a diverse set of substrates such as  
GSK3β, p27KIP1, MDM2, BAD, FOXOs, IKK, TSC2 and PRAS40 to regulate cell cycle 
progression, cell survival, cell growth and cell metabolism (Engelman et al. 2006; Shaw 
and Cantley 2006). Among the variety of pathways downstream of AKT, mTORC1 (one 
of two complexes nucleating mTOR, the other is mTORC2) is essential in regulating cell 
growth through coordinating anabolism including macromolecule synthesis and nutrient 
storage and catabolism like autophagy and utilization of energy stores in response to 
growth factors, nutrients, energy and oxygen level etc. environmental cues (Sengupta et 
al. 2010). mTORC1 is regulated by direct modification of its components or modulation 
of Rheb, a small GTPase that binds and activates mTORC1 when bound to GTP. AKT 
phosphorylates PRAS40 and prevents its binding and inhibition of mTORC1 (Sancak et 
al. 2007; Vander Haar et al. 2007). AKT could also activate mTORC1 by 
phosphorylating and suppressing TSC2 which, together with its partner TSC1, is a 
GTPase-activating protein (GAP) for Rheb (Sancak et al. 2007) (Figure 1-2).  
 
mTORC1 promotes protein synthesis through two of its substrates, the S6 kinases 
(S6Ks) and 4E-BPs which enhance ribosome assembly and mRNA translation. mTORC1 
inhibits autophagy by modulating Atg1/ULK activity in the presence of nutrients and 
growth factors. mTORC1 also controls numerous metabolic pathways including 
glycolysis, sterol and lipid biosynthesis as well as nucleotide metabolism (Sengupta et al. 
2010). Upon activation by growth factors, mTORC1 limits the extent of upstream growth 
factor signaling by a “negative feedback loop”. The best characterized mechanism of the 
“negative feedback loop” is through S6K1 phosphorylation of IRS1 which interferes with 
IRS1 binding to insulin receptor and promotes its degradation, thus preventing over-
activation of the pathway (Harrington et al. 2004; Shah and Hunter 2006). Many 
mTORC1 functions were first discovered by use of the small-molecule rapamycin, an 
allosteric inhibitor of mTOR. Rapamycin forms a complex with protein FKBP12 which 
binds to FRB domain of mTOR and somehow only inhibits mTORC1 activity in acute 
treatment (Huang et al. 2003). For long-term or high dose treatment, rapamycin could 
also inhibit mTORC2 activity by interfering with its assembly (Sarbassov et al. 2006). 
Inhibition of mTORC1 by rapamycin releases the “negative feedback loop” and results in 
enhanced PI3K signaling to AKT (O'Reilly et al. 2006). 
 
Deletion of PTEN will lead to unopposed and constitutive activation of the PI3K-
AKT-mTORC1 pathway. Increases in phosphorylation of AKT serine 473 and threonine 
308, phospho-S6 serine 235/236 (substrate of S6K) and phospho-4EBP1 threonine 37/46 
are often used as the readouts of activated PI3K-AKT-mTORC1 pathway.  
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Figure 1-2. Schematic PI3K signaling pathway. 
The RTK is activated when binding to its ligand and recruits PI3K which phosphorylates 
membrane-bound PIP2 to PIP3. PIP3 recruits AKT and PDK1 to the membrane through 
their PH domain. AKT is fully activated by phosphorylations by PDK1 and mTORC2. 
Activated AKT phosphorylates a diverse set of substrates such as TSC1/2, MDM2, 
FOXO, BAD, NF-kB and GSK3 to regulate processes including cell growth, cell-cycle 
apoptosis, cell metabolism and autophagy. By converting PIP3 back to PIP2 antagonizing 
PI3K activity, PTEN limits and terminates PI3K-AKT signaling. Reprinted with 
permission. Chalhoub, N. and Baker, S.J. 2009. PTEN and the PI3-kinase pathway in 
cancer. Annu Rev Pathol 4: 127-150. Courtesy of Dr. Suzanne Baker. 
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PTEN and Human Diseases 
 
Germline PTEN mutations have been found to occur in several inherited cancer 
and developmental syndromes including 80% of Cowden syndrome (CS), 60% of 
Bannayan-Riley-Ruvalcaba syndrome (BRRS), up to 20% of Proteus syndrome (PS),    
50% of Proteus-like syndrome (PSL) (Eng 2003) and 83% of Lhermitte-Duclos disease 
(LDD) (Zhou et al. 2003). These seemingly unrelated hereditary syndromes are now 
categorized under a unifying molecular-based diagnosis PTEN Hamartoma Tumor 
Syndrome (PHTS) since they share the clinical manifestation of multiple hamartomas and 
have overlapping mutational spectra of PTEN (Eng 2003). Several important clinical 
manifestations of PHTS patients include macrocephaly, multiple hamartomas and cancer 
predisposition in Cowden disease to breast, thyroid, endometrial, colorectal, and renal 
cancers (Riegert-Johnson et al. 2010). 
 
Besides germline mutation, PTEN is also found to be frequently mutated in a wide 
variety of sporadic human cancers. The list of human cancers that harbor PTEN mutation 
has expanded from endometrial, prostate, breast cancers and GBM initially reported in 
1997 to more than ten types (http://www.sanger.ac.uk/genetics/CGP/cosmic/), placing it 
as the second most frequently mutated gene in human cancer. In no doubt this list will 
keep expanding with the advancement of whole genome sequencing technology. 
 
 
PTEN Knock-out Mouse Models outside of the Central Nervous System 
 
 Pten function in development and tumor suppression has been well characterized 
using traditional germline and conditional gene knock-out strategies. Homozygous 
deletion of Pten resulted in embryonic lethality by day 6.5-9.5 because of disrupted 
development of germ layers, while heterozygous mutant mice are predisposed to a variety 
of tumors including lymphomas, intestinal polyps, endometrial hyperplasia, prostate 
intraepithelial neoplasia and thyroid neoplasms (Di Cristofano et al. 1998; Suzuki et al. 
1998; Podsypanina et al. 1999). This spectrum of neoplasias is similar to those in PHTS 
patients. 
 
Cre-LoxP system has allowed people to bypass the embryonic lethality of Pten-/- 
mice and to study Pten function in a tissue-specific manner. Deletion of Pten in T cells 
resulted in hyperproliferation, auto-immunity and T-cell lymphoma (Suzuki et al. 2008). 
Pten deletion in skin lead to epidermal hyperplasia, hyperkaratosis, squamous 
papillomas, squamous cell carcinomas, sebaceous carcinomas and sweat gland 
adenocarcinomas (Suzuki et al. 2008). Hepatocyte-specific Pten knock-out caused 
massive hepatomegaly, steatohepatisis, liver adenomas and hepatocellular carcinomas 
(Suzuki et al. 2008). Deletion of Pten in urothelial cells resulted in urothelial hyperplasia 
and hypertrophy and transitional cell carcinomas (Suzuki et al. 2008). Most of mice with 
bronchioalveolar epithelium-specific inactivation of Pten died of hypoxia at birth and the 
rest developed spontaneous lung adenocarcinomas (Suzuki et al. 2008). Pten is also 
required for normal blood vessel remodeling and suppressing tumor angiogenesis (Suzuki 
et al. 2008). Pten has an essential role in restricting the activation of hematopoietic stem 
6 
 
cells and preventing leukaemogenesis. Inactivation of Pten in the bone marrow resulted 
in a short-term expansion but long-term decline of hematopoietic stem cells and eventual 
leukemia formation (Yilmaz et al. 2006; Zhang et al. 2006). Oocyte-specific deletion of 
Pten causes premature activation of the primordial follicle pool and premature ovarian 
failure (Reddy et al. 2008). Conditional Pten knock-out mice have also been generated 
that develop teratomas, pancreatic cancers, cholangiocellular carcinomas and 
leiomyosarcomas (Suzuki et al. 2008). 
 
 
PTEN in Neuropathology and Neural Development 
 
 
Pten function in neurons 
 
PTEN inactivation in the cerebellum causes LDD or dysplastic gangliocytoma of 
the cerebellum, a hamartomatous lesion in the cerebellum. LDD patients manifest with 
progressive macrocephaly, seizure, ataxia and mental retardation. The typical 
pathological feature of LDD is the diffusely hypertrophic and disorganized cerebellar 
folia with replacement of the Purkinje and granule cells by hypertrophic ganglionic 
neurons (Abel et al. 2005). The features of LDD were recapitulated by mouse models in 
which Pten was conditionally deleted in cerebellar granule cells during development. 
Pten deletion resulted in progressive increase in brain size, seizures, neuronal 
hypertrophy and migration defect demonstrating that Pten regulates neuronal size and 
migration (Backman et al. 2001; Kwon et al. 2001). PHTS patients also exhibit autistic 
behavior and mental retardation with decreased or delayed learning (Goffin et al. 2001; 
Eng 2003). Interestingly, a mouse model deleting Pten in differentiated neurons in the 
cerebral cortex and hippocampus showed similar autistic features to human patients 
including abnormal social interaction, anxiety-like behavior and decreased learning 
(Kwon et al. 2006). These neurological and behavioral manifestations could be 
presumably explained by the abnormalities in neuronal structure and function caused by 
Pten deficiency such as hypertrophic and ectopic dendrites, increased dendritic spine 
density, increased axonal synapses, severe myelination defects, weakened synaptic 
transmission and synaptic plasticity (Kwon et al. 2006; Fraser et al. 2008). 
 
 
Pten function in glia 
 
The axons of neurons are usually ensheathed by myelin which is formed by 
oligodendrocytes in the central nervous system (CNS) or Schwann cells in the peripheral 
nervous system (PNS). Abnormalities in myelination underlie a variety of human 
diseases such as multiple sclerosis, Guillain-Barré Syndrome, central pontine myelinosis, 
inherited demyelinating diseases like Leukodystrophy and Charcot Marie Tooth (Suter 
and Scherer 2003). One histopathological feature in LDD patients is the abnormal 
myelination in the cerebellar molecular layer (Abel et al. 2005) suggesting Pten might be 
involved in the regulation of myelination. Recent studies in mouse models just started to 
reveal Pten function in the oligodendrocytes and Schwann cells. Pten deletion in either 
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developing or differentiated oligodendrocytes and Schwann cells resulted in dramatic 
hypermyelination (Fraser et al. 2008; Goebbels et al. 2010; Harrington et al. 2010). The 
hypermyelination was caused by oligodendrocyte hypertrophy and increased thickness of 
myelin sheath but not change in the number of oligodendrocyte in the CNS. In the PNS, 
however, Pten loss caused an increased number of Schwann cells and de novo 
myelination of normally non-myelinated nerve fibers as well as increased thickness of 
myelin sheath. Rapamycin treatment strongly impeded the volume increase of the white 
matter indicating that the AKT/mTOR pathway is one critical downstream effector in the 
differentiation of oligodendrocytes (Goebbels et al. 2010). There was also massive axon 
degeneration associated with progressive myelin sheath abnormalities. However, there 
was no detectable improvement in remyelination following white matter injury. These 
studies indicate that Pten is required to regulate myelin thickness and preserve axon 
integrity but dispensable during myelin repair (Harrington et al. 2010). Pten is also 
required for the Dlg1-mediated myelination brake whose failure causes Schwann cell 
hypermyelination with focally folded myelin, a hallmark of one type of Charcot-Marie-
Tooth disease (Cotter et al. 2010). In addition, Pten also inhibits oligodendrocyte 
progenitor cell proliferation and promotes their differentiation (Paintlia et al. 2010). 
 
Astrocytes are another large population of glial cells that provide structural 
support, regulate water balance and ion distribution and maintain the blood-brain barrier 
etc (Rowitch and Kriegstein 2010).  Only very few studies have been conducted on Pten 
function in the development of astrocytes in their physiological environment. A mouse 
model inactivating Pten in both astrocytes and neurons during development showed 
increased cell size and proliferation in the astrocytes in contrast to the increase in cell size 
only in the neurons (Fraser et al. 2004). However, whether or not the hypertrophy and 
hyperproliferation in the astrocytes are cell-autonomous still needs further investigation 
because astrocytosis (an abnormal increase in the number of astrocytes) is a known 
phenomenon of astrocytes in response to environmental stresses such as neuron damage. 
Deletion of Pten in astrocytes in the adult brain resulted only in a slightly increased Gfap 
expression (Chow et al. 2011). 
 
 
Pten function in neural stem cells 
 
Inactivation of Pten by a Nestin promoter driven Cre in the neural stem/progenitor 
cells at midgestation demonstrated that mutant mice exhibit enlarged, histoarchitecturally 
disrupted brains, which resulted from increased cell proliferation, decreased cell death 
and enlarged cell size. Neurosphere cultures further showed increased proliferation and 
self-renewal capacity for Pten deficient neural stem/progenitor cells with no deficit in 
differentiation (Groszer et al. 2001; Groszer et al. 2006). These studies indicate Pten 
negatively controls proliferation and self-renewal of neural stem/progenitor cells during 
early brain development. However, the Nestin-Cre;PtenloxP/loxP mice die soon after birth 
precluding investigation of Pten function in neural stem/progenitor cells in early postnatal 
days and adulthood. 
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PTEN and Brain Tumorigenesis 
 
 
Postnatal brain development and neural stem cells in adulthood 
 
The bulk of brain structure changes relatively little after birth except the 
cerebellum, hippocampus and subventricular zone (SVZ) where neurogenesis and 
neuronal migration continue in postnatal days and adults. Although the establishment of 
the cerebellar territory and generation of Purkinje neurons and deep cerebellar nuclei 
happen during embryogenesis, most granule neurons are generated postnatally. Granule 
neuron progenitors migrate superficially from rhombic lip to form the external granule 
layer (EGL) on the surface of the cerebellum at embryogenesis. These cells continue 
proliferating and generate granule cells which descend into the cerebellum and form the 
internal granule layer (IGL) until postnatal day 21 in mouse and up to year 2 in human 
(Figure 1-3A). Active postnatal development makes cerebellum very susceptible to 
mutagenesis. It is the most common site of origin for pediatric solid tumors, accounting 
for 15.6% of all primary brain and CNS tumors in childhood (CBTRUS 2010). 
 
Neural stem cells or neural precursor cells in adulthood are mainly restricted to 
the hippocampus and SVZ in the brain where neurogenesis occurs throughout life. In 
mouse, it has been shown that thousands of new neuronal precursors are born every day 
in the SVZ and migrate through the rostral migratory stream (RMS) to the olfactory bulb 
(OB) where they differentiate into interneurons and are integrated into local circuits. 
Migrating neuronal precursor cells or neuroblasts (Dcx+) are differentiated from Mash1+ 
transit amplifying cells which in turn are generated by Gfap+ neural stem cells in the 
SVZ (Alvarez-Buylla and Garcia-Verdugo 2002) (Figure 1-3B, C). SVZ has also been 
found to be conserved in human brain (Quinones-Hinojosa et al. 2006; Curtis et al. 2007). 
However whether or not the RMS is present in human brain is still controversial (Sanai et 
al. 2004; Curtis et al. 2007; Guerrero-Cazares et al. 2011). In hippocampus, new neurons 
are continously generated in the subgranular zone (SGZ) of dentate gyrus and migrate 
outward for a short distance to be incorporated into dentate gyrus. Neural stem/progenitor 
cells in the SVZ-RMS-OB and the SGZ are thought to play an important role in damage 
repair and the process of memory formation (Gage 2002; Ming and Song 2005; 
Ghashghaei et al. 2007). They might also serve as cells of origin for brain tumors because 
of their great proliferative capacity. 
 
Unlike the neurogenesis which occurs before gliogenesis during brain 
development and peaks at embryonic day 14 (E14), astrocytes and oligodendrocytes, two 
major glial cells in the brain are generated mainly postnatally peaking at P2 and P14, 
respectively (Sauvageot and Stiles 2002). Mature astrocytes and oligodendrocytes are 
able to proliferate in physiological condition or pathologically in response to injury. They 
are thought to be the other candidate cells of origin for primary brain tumors besides 
neural stem/progenitor cells. It is still largely unclear whether gliomas arise from neural 
stem/progenitor cells or from fully differentiated astrocytes or oligodendrocytes, the two 
most possible cell sources maintaining proliferation capacity in the brain for malignant 
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Figure 1-3. Postnatal development of mouse brain. 
(A) Nissl staining of saggital mouse brain at age P4. Neurogenesis is still actively 
ongoing in postnatal brain in two places. First, new neuronal progenitors (or neuroblasts) 
arise from neural stem cells in the subventricular zone (SVZ) in the lateral walls of lateral 
ventricles (LV), migrate through the rostral migratory steam (RMS) to the olfactory bulb 
(OB) where they terminally differentiate and are integrated into local neural circuits. 
Second, granule cell progenitors actively proliferate in the external granule layer (EGL) 
of the cerebellum (CB), then migrate inward and differentiate forming the internal 
granule layer (IGL) during early postnatal days. (B) Nissl staining of coronal mouse brain 
of age P28 shows the SVZ. (C) Cell lineage in the SVZ. Neural stem cells (B cells) give 
rise to transit amplifying cells (C cells) which in turn generate neuroblasts (A cells). E 
cells are ependymal cells lining the LV. Panel C is Modified with permission. Alvarez-
Buylla, A. and Garcia-Verdugo, J.M. 2002. Neurogenesis in adult subventricular zone. J 
Neurosci 22(3): 629-634. 
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transformation. The identification of cell origins of gliomas will not only improve our 
knowledge but also help develop therapeutic strategies of this disease.  
 
 
Primary brain tumors 
 
In the United States in the year 2010, there was an estimated 62,930 new cases of 
primary non–malignant and malignant brain and CNS tumors (CBTRUS 2010). Primary 
malignant brain and CNS tumors account for 1.4 percent of all cancers, 2.3 percent of all 
cancer deaths and 21.3 percent of pediatric cancers (ACS 2010). Meningioma, gliomas 
and pituitary tumor are the most common histology types of primary brain tumors in 
adults. Gliomas including astrocytoma, glioblastoma, oligodendroglioma, ependymoma 
and mixed gliomas etc. represent 32% of all primary brain tumors and 80% of malignant 
primary brain tumors. GBM (WHO grade IV) is the most malignant form and accounts 
for 53.8% of all gliomas (CBTRUS 2010) (Figure 1-4A). The median survival of GBM 
patients ranges from 9 to 12 month despite combined treatment of surgery, radiotherapy 
and chemotherapy. The survival rate for GBM has not been improved and no effective 
agents have emerged for over two decades (Furnari et al. 2007). 
 
In children, brain tumors are the most common type of solid tumor and the 
incidence is about 4.7 per 100,000 person–years in the US. Pilocytic astrocytoma, 
malignant glioma and medulloblastoma are the most common individual histologies. 
Gliomas are the most frequent primary brain tumors in childhood accounting for about 
50% of all tumors and 70% of malignant tumors. Embryonal tumors including 
medulloblastoma (WHO grade IV) are the second most common malignant form and 
account for 13.7% of all pediatric brain tumors among 0-14 years olds (CBTRUS 2010) 
(Figure 1-4B). While the 5-year survival rate of medulloblastoma patients has achieved 
60% after treated with radio- and chemotherapy, the patients often suffer from side 
effects such as cognitive impairment and psychiatric disorders.  
 
Overall, malignant glioma (WHO grade III and IV) and medulloblastoma, the 
most common primary brain tumors in adults and children, pose a big challenge to 
healthcare and await novel therapies. 
 
 
PTEN mutations in brain tumors 
 
One genetic abnormality that is frequently seen in adult and pediatric brain tumors 
is the loss of chromosome 10q where PTEN is located. Losses of chromosome 10q have 
been reported to occur in 60-80% of GBM (Ohgaki and Kleihues 2007) and 25-30% of 
medulloblastoma (McCabe et al. 2006; Rossi et al. 2006; Lo et al. 2007). 
 
PTEN is reported to be mutated in 15-40% of GBM but is rare in low-grade 
gliomas (Ohgaki and Kleihues 2009) suggesting PTEN mutation is a late event in 
glioblastomagenesis. This is in contrast to some other mutations such as TP53 which 
occurs at the same frequencies in both low and high grade gliomas. Besides PTEN, 88% 
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Figure 1-4. Distributions of primary brain and CNS tumor by histology. 
(A) Distribution of all primary brain and CNS tumors by histology. (B) Distribution of 
childhood primary brain and CNS tumors by histology (Ages 0-14). Source: CBTRUS. 
2010. CBTRUS statistical report: primary brain and central nervous system tumors 
diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United 
States, Hinsdale.  
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of GBM samples harbored at least one genetic abnormality in the RTK/PI3K pathway 
including EGFR mutation and amplification (45%), ERBB2 mutation (8%), PDGFRA 
amplification (13%), PIK3CA (15%), NF1 mutation (18%) and other less common 
genetic changes (TCGA 2008). RTK/PI3K pathway together with p53 (87%) and RB 
(78%) tumor suppressor pathways comprised the three core pathways that were altered in 
GBM (Parsons et al. 2008; TCGA 2008). 
 
Numerous human genomic analyses and mouse modeling studies have 
underscored the pivotal role of the sonic hedgehog (SHH) pathway in medulloblastoma 
pathogenesis. The binding of SHH to its receptor PTCH1 relieves its inhibition on SMO 
and allows the release of the transcription factor Gli from the inhibitory complex 
containing SUFU trans-activating downstream effector genes in the nucleus. SHH 
signaling plays an important role in driving proliferation of granule cell progenitors in the 
EGL of cerebellum. Inactivating mutations of PTCH1 and SUFU and activating 
mutations of SMO have been found in 15-25% of sporadic medulloblastoma (Raffel et al. 
1997; Reifenberger et al. 1998; Taylor et al. 2002; Parsons et al. 2011). The second 
signaling pathway that is frequently altered in the development of medulloblastoma is the 
Wnt pathway in which mutations in APC, AXIN or CTNNB1 occur in 20% of the samples 
(Zurawel et al. 1998; Huang et al. 2000; Baeza et al. 2003; Parsons et al. 2011). Recent 
whole genome sequencing analysis also revealed new genetic alterations in this disease 
such as mutations in the histone-lysine N-methyltransferase MLL2 and MLL3 (20%) and 
PTEN (3/88) as well as other genetic changes like TP53 (6/88), MYC (3/88) and OTX2 
(2/88) which have been implicated in medulloblastoma previously. Interestingly, three of 
the medulloblastomas with PTEN mutation also had either TP53 or PTCH1 mutation 
suggesting potential co-operational effect among them (Parsons et al. 2011). 
 
 
Specific PTEN functions in brain tumors 
 
Numerous studies in the past using glioma cell lines and xenograft models have 
revealed various aspects of PTEN tumor suppressor functions. For instance, re-expression 
of PTEN in the PTEN-deficient glioblastoma cell line could suppresses proliferation in 
vitro by arresting cells in the G1 phase of the cell cycle through a p27Kip1-dependent 
manner (Furnari et al. 1998; Gottschalk et al. 2001). Reintroduction of PTEN into human 
glioma cell lines could inhibit the in vitro invasiveness which is associated with reduced 
activity of matrix metalloproteinases including MMP2 and MMP9 (Koul et al. 2001; 
Kubiatowski et al. 2001). PTEN reconstitution also decreased the growth of orthotopic 
transplants of human glioma cell lines in nude mouse brain by reducing angiogenesis. 
This was due to PTEN function in induction of thrombospondin1 expression which 
inhibited angiogenesis and inhibition of HIF-1 α that induces angiogenesis (Wen et al. 
2001; Pore et al. 2006). However most human glioma cell lines have been maintained and 
passaged in tissue culture for decades. They have adapted to animal serum that is 
different from the brain environment they originally arise from. These cell lines often do 
not show the classical histologic appearance of human gliomas any more (Lee et al. 
2006a) and are not predictive for response for clinical trials (Voskoglou-Nomikos et al. 
13 
 
2003). In addition, cell culture system is unable to model cancer invasion, angiogenesis, 
metastasis and the role of microenvironment in drug response.  
 
Because of the limitations of cell line studies, genetically engineered mouse 
models with a close genetic resemblance to human disease have been utilized to better 
model human brain tumors. Several genetic mouse models of human glioma and 
medulloblastoma by knocking out Pten in combination with engineering of other disease-
relevant genes have been published in recent years that provide new insights into these 
diseases as well as Pten tumor suppressor function in the brain tumors. Specific deletion 
of Trp53 and Pten with Cre/loxP system in the mouse CNS generated spontaneous high-
grade gliomas resembling human GBM. Inactivation of p53 and Pten promotes 
maintenance of mouse neural and glioma stem/progenitors in an undifferentiated state 
with high renewal potential by increasing Myc expression (Zheng et al. 2008). 
Haploinsufficiency of Pten could accelerate development of grade III astrocytomas 
generated by concomitant deletion of Trp53 and Nf1 and loss of Pten heterozygosity 
promoted progression into GBM (Kwon et al. 2008). Further study demonstrated specific 
inactivation of Trp53, Nf1 and Pten in neural stem/progenitor cells in the SVZ was both 
necessary and sufficient to induce astrocytoma formation suggesting neural 
stem/progenitor as cells of origin for human GBM (Alcantara Llaguno et al. 2009). 
Another study provides similar evidence by showing that brain tumors arose from 
deleting Rb;Trp53, Rb;Trp53;Pten or Pten;Trp53 in adult SVZ neural stem cells but not 
in mature astrocytes. This study also demonstrates that genetic mutations might specify 
brain tumor phenotypes since inactivation of Pten;Trp53 gave rise to gliomas whereas 
deletion of Rb;Trp53 or Rb;Trp53;Pten generated primitive neuroectodermal tumours 
(PNET) (Jacques et al. 2010). However, in another study all these combinations of tumor 
suppressor inactivation give rise to high-grade gliomas but not PNET (Chow et al. 2011). 
This discrepancy might be explained by the different strategies of gene inactivation 
between these two studies. The high-grade gliomas generated by Chow et al. (2011) 
mimic the expression profiling of human disease and arise from within and outside of the 
proliferative niches which demonstrates the relevance of the genetically engineered 
mouse models to human gliomas and also suggest that cells other than neural stem cells 
could serve as the origin of human gliomas.  
 
In a mouse medulloblastoma model driven by Shh overexpression, Pten loss is 
shown to confer radiation resistance to cancer stem cells in the perivascular niche that is 
responsible for the tumor recurrence after irradiation (Hambardzumyan et al. 2008). Pten 
loss could also promote tumorigenesis in a mouse model of medulloblastoma driven by 
constitutive activation of SmoA1 and is associated with poor prognosis with clinical 
patients (Castellino et al. 2010). Interestingly, Pten is spontaneously lost in combination 
with biallelic inactivation of Ptch1 in the mouse medulloblastoma initiated with disrupted 
homologous recombination indicating a cooperation effect of PI3K and Shh pathway in 
medulloblastoma pathogenesis (Frappart et al. 2009). 
 
Although past work has revealed various Pten functions in brain development and 
tumorigenesis, many questions still remain. How does loss of Pten cause the ectopic 
positioning of neurons? Is Pten involved in regulating directional migration as it is in 
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Dictyostelium? How does the migration of Pten-null neuronal progenitors change 
compared to their wild-type counterparts? How will inactivation of Pten affect the neural 
stem/progenitor cells postnatally? Is loss of Pten in the neural stem/progenitors sufficient 
for brain tumorigenesis? What are other cells of origins for brain tumors besides neural 
stem cells in the SVZ? In the present study, we deleted Pten as well as other tumor 
suppressor genes in neural stem/progenitors using Nestin-CreERT2 transgenic mice to 
address these questions. 
  
15 
 
CHAPTER 2.    PTEN DELETION IN THE SUBVENTRICULAR ZONE CAUSES 
MTORC1-DEPENDENT ECTOPIC DIFFERENTIATION OF 
NEUROBLASTS WITHOUT DISRUPTING DIRECTIONAL MIGRATION 
 
 
Introduction 
 
In rodent brain, thousands of new neuronal precursors arise every day in the SVZ, 
the postnatal neural stem cell niche in the lateral walls of the lateral ventricles. 
Neuroblasts migrate from the SVZ through the rostral migratory stream (RMS) to the 
olfactory bulb (OB) where they differentiate into interneurons and are integrated into 
local circuits. Multiple cell types reside in this niche including Gfap-expressing neural 
stem cells which generate Mash1-expressing transit amplifying cells. Transit amplifying 
cells further differentiate into migrating neuronal precursor cells or neuroblasts that 
express the microtubule associated protein, Dcx (Alvarez-Buylla and Garcia-Verdugo 
2002). In human brain, the SVZ niche harboring neural stem cells is conserved 
(Quinones-Hinojosa et al. 2006; Curtis et al. 2007), however the presence and cellular 
composition of the RMS remains somewhat controversial (Sanai et al. 2004; Curtis et al. 
2007; Guerrero-Cazares et al. 2011). Although work conducted during recent years has 
unraveled many signals regulating the tangential migration from the SVZ to the OB, the 
extracellular cues and signaling pathways instructing when and where these tangentially 
migrating interneurons stop are largely unknown. 
 
 PI3Ks are an evolutionarily conserved family of lipid kinases that phosphorylate 
the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides, essential regulators 
of diverse cellular processes including proliferation, survival, apoptosis, autophagy, 
growth, metabolism and cell migration (Engelman et al. 2006). Downstream of PI3K, 
Akt-mTorc1 signaling is a crucial branch of the pathway controlling protein synthesis, 
cell growth, autophagy and metabolism. Deregulation of the PI3K-Akt-mTorc1 pathway 
is associated with a variety of human genetic diseases, for instances, inherited mutations 
in TSC1 or TSC2 cause tuberous sclerosis; NF1 mutation results in neurofibromatosis 
type1; and PTEN mutations underlie CS, BRRS, LDD and Proteus syndrome (Inoki et al. 
2005; Rosner et al. 2008). Patients with these inheritable diseases frequently manifest 
neurological abnormalities indicating that proper PI3K-Akt-mTorc1 pathway activity is 
important in normal neural development and/or function. Conditional mouse models 
knocking out the individual component genes in the brain recapitulate human diseases 
and further underscore the importance of PI3K-Akt-mTorc1 pathway regulation of neural 
development. Mice with neuron-specific ablation of Nf1 have relatively normal neuronal 
development but display a reduced cerebral cortex and extensive reactive astrogliosis 
(Zhu et al. 2001). Deletion of Nf1 in astrocytes resulted in glial hyperplasia and optic 
nerve glioma (Bajenaru et al. 2003; Zhu et al. 2005) which is a hallmark of 
neurofibromatosis type1 patients. Mice deleted of Tsc1 or Tsc2 in neural progenitor or 
neurons demonstrated disrupted cortical and hippocampal lamination, ectopic dysplastic 
neurons as well as abnormal myelination and astrocytosis which recapitulate the 
neuropathology in tuberous sclerosis patients (Meikle et al. 2007; Way et al. 2009).  
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Pten, an important tumor suppressor gene, is a major negative regulator of the 
PI3K pathway. It functions as a lipid phosphatase antagonizing the activity of PI3Ks by 
catalyzing dephosphorylatation of PIP3 to PIP2. Pten plays a number of roles in brain 
development including negatively regulating self-renewal and proliferation of neural 
stem cells (Groszer et al. 2001) and controlling neuronal size (Backman et al. 2001; 
Kwon et al. 2001). A pronounced phenotype in the brain of Pten knock-out mice is the 
disrupted lamination and ectopic differentiation of neurons, which had been attributed to 
failed neuronal migration (Backman et al. 2001; Groszer et al. 2001; Kwon et al. 2001; 
Marino et al. 2002; Yue et al. 2005). However, the underlying mechanism of how Pten is 
involved in neuronal migration is currently unknown. 
 
In the present study, we demonstrate that Pten inhibits downstream activation of 
mTorc1 in normal migrating neuroblasts in the RMS. Deletion of Pten in the SVZ and 
RMS caused ectopic differentiation of neuroblasts without disrupting the directional 
migration in the RMS. 
 
 
Experimental Procedures 
 
 
Mice 
 
Nestin-CreERT2 mice (Cicero et al. 2009) were generated using a transgene 
containing the Nestin promoter and second intron (Zimmerman et al. 1994) to direct 
expression of CreERT2 (Metzger et al. 1995; Feil et al. 1996; Feil et al. 1997), an internal 
ribosomal entry site (IRES), and human placental alkaline phosphatase (hPLAP) 
specifically in progenitor cells in the central nervous system. To map tamoxifen induction 
of Cre activity, Nestin-CreERT2 transgenic mice were bred with R26R-LacZ (Soriano 
1999) or R26R-EYFP (Srinivas et al. 2001) mice to generate Nestin-CreERT2;R26R-LacZ 
or Nestin-CreERT2;R26R-EYFP mice. Cre reporter activity was detected by X-gal 
staining or EYFP IF staining on frozen tissue sections. Pten conditional knock-out mice 
(Nestin-CreERT2; PtenloxP/loxP, or R26R-EYFP;PtenloxP/loxP for Cre electroporation 
experiments) were generated by intercrossing Nestin-CreERT2 or R26R-EYFP transgenic 
mice to PtenloxP mice (Suzuki et al. 2001), a gift from Tak Mak (University of Toronto, 
Toronto). For all analyses including Nestin-CreERT2, the transgene was hemizygous to 
avoid possible variation from transgene dosage. Littermate PtenloxP/loxP mice without the 
Nestin-CreERT2 transgene were used as control and processed the same way as PtencKO 
mice. All procedures were reviewed and approved by the Animal Care and Use 
Committee at St. Jude Children's Research Hospital. 
 
 
Genotyping polymerase chain reaction assays 
 
Polymerase chain reaction (PCR) was used to genotype mice. Primers used are: 
Cre, forward primer: 5’AGCGATCGCTGCCAGGAT; reverse primer: 
5’ACCAGCGTTTTCGTTCTGCC; expected product: 157 base pairs. Pten, forward 
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primer: 5’TTATCTGGATCAACTTTGGGCC; reverse primer: 
5’TCCCACCAATGAACAAACAGT; expected products: 146 (wild-type) and 244   
(loxP) base pairs. 
 
 
Induction of Cre activity 
 
Tamoxifen (TM) (Sigma) was dissolved at 20mg/ml or 5 mg/ml at 37°C in corn 
oil (Sigma) for Cre induction in adult mice or pups respectively. Dissolved TM was 
sterilized by filtering and stored at 4°C in the dark for up to 10 days. Pups were injected 
with 3 mg/40g TM introperitoneally (i.p.) daily from P0-1 or P11-12 as indicated. Adult 
mice were injected with 9 mg/40g TM i.p. daily from P28-30. An equivalent volume of 
sterile filtered corn oil alone was used for vehicle injections. Multiple injections in the 
same mouse were separated by 24 hours. 
 
 
5-Bromo-2’-deoxyuridine injection and rapamycin treatment 
 
5-Bromo-2’-deoxyuridine (BrdU) (Sigma) was dissolved at 5 mg/ml in sterile 
phosphate buffered saline (PBS) and stored at -20°C. BrdU was injected i.p. at a dose of 
50 μg/g body weight every 2 hours for 5 injections for short-term BrdU labeling or every 
12 hours for 6 times from P4-P6 for BrdU birthdating experiment. 
 
Rapamycin (LC Laboratories) was dissolved at 20 mg/ml in sterile dimethyl 
sulfoxide (DMSO), stored at -20°C and diluted in 5.2% Tween80 as working solution 
before use. Rapamycin was injected i.p. at 1.5 μg/g body weight daily from P8-P31 of 
age. An equivalent volume of sterile DMSO+Tween80 alone was used for vehicle 
injections. When TM was given on the same day, the two drugs were separated by 6 
hours. 
 
 
Histochemistry 
 
Mice were anesthetized and perfused transcardially with PBS followed by 2% 
paraformaldehyde (PFA) in PBS. Following dissection, tissues were post-fixed overnight 
in 2% PFA in PBS at 4°C, and then equilibrated in 25% sucrose in PBS for an additional 
24 hours at 4°C. Tissues were embedded in TBS embedding media (Triangle Biomedical 
Sciences) on dry ice and cryosectioned at thickness of 12 μm. Tissue slides were 
equilibrated at room temperature for 20 minutes then washed three times in PBS prior to 
staining. 
 
For detection of β-galactosidase activity, slides were washed in Rinse A (100 mM 
NaPO4, pH 7.3; 2 mM MgCl2; 5 mM EGTA) for 30 min followed by Rinse B (100 mM 
NaPO4 pH 7.3; 2 mM MgCl2; 0.01% sodium deoxycholate; 0.02% NP-40) for 5 min. 
Slides were then stained at 37°C for overnight in Developing Buffer (1 mg/ml X-gal; 100 
mM NaPO4; pH 7.3; 2 mM MgCl2; 0.01% sodium deoxycholate; 0.02% NP-40; 5 mM 
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K3Fe(CN)6; 5 mM K4Fe(CN)6). After washing in PBS, slides were counterstained with 
Nuclear Fast Red (Vector Labs). 
 
 
Immunohistochemistry and immunofluorescence 
 
Cryosections were prepared as described above. For paraffin sections, mice were 
processed the same way as above except the PFA concentration was 4%PFA. Following 
perfusion, tissues were post-fixed for an additional 24 hours in 4% PFA, embedded in 
paraffin, and cut into 5 μm sections. Primary antibodies used for immunostaining were 
against GFP (1:1000, Invitrogen A6455; 1:2000, Abcam #13970), Pten (1:100 for 
immunohistochemistry (IHC), 1:500 for immunofluorescence (IF) with Tyramide 
amplification, Cell Signaling #9559), p-Akt S473 (1:50, Cell Signaling #9271), p-S6 
S235/236 (1:500, Cell Signaling #2211), Dcx (1:4000 for IHC, 1:500 for IF, Chemicon 
AB5910), Mash1 (1:100, BD #556604), NeuN (1:500, Chemicon), Map2 (1:5000, 
Sternberger SMI52), Calretinin (1:2000, Chemicon AB149), Gfap (1:200, Sigma  
G3893), Ki67 (1:5000, Novocastra NCL-Ki67p), BrdU (1:1000, AbDSerotec 
OBT0030CX) and active Caspase3 (1:1000, BD #559565). For IHC, microwave antigen 
retrieval was performed for all antibodies and biotinylated secondary antibodies were 
used in conjunction with horseradish peroxidase-conjugated streptavidin (Elite ABC, 
Vector Laboratories). Tyramide Signal Amplification (Perkin Elmer) was used to 
improve Pten IF and p-Akt S473 signal. Color development was conducted with 
substrates NovaRed, DAB or VIP (Vector Laboratories) and counterstaining with 
hematoxylin or methyl green (Vector Laboratories), respectively. For IF, Alexa Fluor 
488, 647 (Invitrogen) and cyanine 3, 5 (Jackson Immunoresearch) conjugated secondary 
antibodies were employed along with Vectashield mounting media containing 4′,6-
diamidino-2-phenylindole  (DAPI) (Vector Laboratories). Terminal deoxynucleotidyl 
transferase-mediated nick end labeling (TUNEL) staining was conducted with the 
ApopTag peroxidase in situ apoptosis detection kit (Chemicon S7100) according to the 
manufacturer’s protocol. 
 
 
Ki67 and BrdU positive cell quantification 
 
Ki67 or BrdU immunostaining from anatomically matched sections were chosen 
for quantification. For proliferation analyses, the Bioquant system (R&M Biometrics) 
was used to count all the Ki67+ cells in the SVZ. For the BrdU birthdating experiment, 
BrdU+ cell number and granule cell density in a field of 20x objective in the same areas 
of the OB granule cell layer (GCL) or total number of BrdU+ cell in the SVZ were 
counted with ImageJ v1.44 cell counter. Four controls and four PtencKO brains were 
analyzed for each group and positive cells were counted from three sections from each 
brain for each staining. Student’s t-test was used for statistical significance analysis. 
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In vivo electroporation 
 
In vivo electroporation was performed using a similar approach to previous 
reports (Boutin et al. 2008; Chesler et al. 2008). 2 ul of endotoxin-free pCAG-Cre 
expression plasmid (0.65 μg /μl, in PBS containing 1% fast green) was injected into the 
lateral ventricle of P2 pups with a 30G needle Hamilton syringe using the midpoint 
between Bregma and Lambda and 1mm lateral to the midline suture as landmarks for 
injection. Fast green dye allowed visual confirmation of correct injection into lateral 
ventricles. Only successfully injected animals were subjected to five square-wave 
electrical pulses (50 ms separated by 950 ms intervals, 150v). Electroporated pups 
recovered on a 37°C heating pad before returning to the mother. 
 
 
Brain slice preparation, time-lapse live imaging and migration analysis 
 
Mouse brains were quickly removed and placed in sterile filtered cold (4°C) 
dissecting Complete Hank’s Balanced Salt Solution (Complete HBSS) containing 1x 
HBSS (GIBCO), 2.5 mM Hepes (pH 7.4, GIBCO), 30 mM D-glucose, 1 mM CaCl2, 1 
mM MgSO4, and 4 mM NaCO3 (Polleux and Ghosh 2002). After dissection, brains were 
embedded in 3% low-melting point agarose (Promega) and cut into 300 μm thick sections 
saggitally with a vibratome. Slices containing the RMS were identified by EYFP 
expression, equilibrated for 2 hours in artificial cerebrospinal fluid (aCSF) containing 125 
mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 1.25 mM NaH2PO4, 26 mM 
NaHCO3, and 20 mM D-glucose (285-295 mOsm) with 95% O2 / 5% CO2 at room 
temperature and then transferred into the submerged recording chamber and superfused 
(1-2 ml/min) with warm (36-37°C) aCSF. Time-lapse live imaging was acquired by two-
photon laser-scanning microscopy equipped with an Ultima imaging system (Prairie 
Technologies), a Ti:sapphire Chameleon Ultra femtosecond-pulsed laser (940 nm) 
(Coherent), and a 20x 0.95 numerical aperture water-immersion infrared objective 
(Olympus). Z stacks (512 x 512 pixels, 0.079 µm/pixel, 60-100 sections per stack, 
1µm/section) were collected at the elbow of the RMS every 5 minutes for 3-6 hours. 
 
Average projections of 20 consecutive sections in the middle of z-stacks of time-
lapse live imaging were analyzed using SlideBook v5.0 (Intelligent Imaging  
Innovations). Cells that exhibited bipolar morphology and moved at least two cell body 
lengths were counted as "bipolar migrating cells". All other cells were considered 
"stationary or non-polar cells". For each movie, all the EYFP+ cells were manually 
tracked but only those that could be observed more than 5 consecutive frames were 
included in the analysis. The average speeds (total displacement / time) or endpoint 
speeds (the distance between the first and last timepoints of the path / time) were binned 
in 0.005 µm/second interval to obtain a distribution. χ2  analysis or Student’s t-test was 
used to assess if the distributions or means, respectively, of average speeds (or endpoint 
speeds) were significantly different. 
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Results 
 
 
PI3K pathway activity in the wild-type SVZ-RMS-OB 
 
To understand how PI3K signaling is regulated in the SVZ-RMS-OB, we 
examined expression of several key components of the pathway. Levels of Pten 
expression were heterogeneous in the SVZ and all of the cells expressing Pten were Dcx+ 
neuroblasts (Figure 2-1A). In the SVZ and proximal RMS, the majority of cells 
expressing p-S6, a downstream indicator of PI3K/mTorc1 pathway activity, were 
Mash1+ transit amplifying cells, and not Dcx+ migrating neuroblasts (Figure 2-1B and 
data not shown). In contrast, in the terminal RMS at the OB core, a substantial population 
of Dcx+ type A cells expressed p-S6 (Figure 2-1C). This indicates that the PI3K pathway 
was not strongly active in migrating neuroblasts until these cells reached their destination 
in the OB. 
 
 
Postnatal deletion of Pten caused ectopic differentiated neurons in an expanded 
SVZ and proximal RMS 
 
To evaluate the function of the PI3K pathway regulator Pten in postnatal neural 
stem/progenitors, we generated Nestin-CreERT2 mice with inducible Cre activity in the 
SVZ (Figure 2-2), and bred them to PtenloxP/loxP (Suzuki et al. 2001) to generate inducible 
Pten conditional knockout mice (hereafter PtencKO). Induction of Pten deletion in adult 
SVZ by TM injection in PtencKO mice at P30-P32 did not cause obvious neurological 
abnormalities throughout a normal lifespan except for occasional seizures in some aged 
animals. Analysis of all PtencKO brains (n=24) showed dramatic expansion of the SVZ 
(Figure 2-3A) and proximal RMS (Figure 2-4). The expansion was most pronounced at 
the dorsal junction of the SVZ abutting the corpus callosum and the ventral tip where it 
formed a bulb-like structure. The expansion started to appear as early as 20 days post 
induction (DPI) and was similar at 60, 150, 300, and 540 DPI without progressive 
enlargement at later time points. IHC analysis showed the expanded SVZ was uniformly 
negative for Pten staining with marked elevation of p-Akt indicating overall activation of 
the PI3K pathway in the entire region (Figure 2-3B, C). 
 
When conditional Pten deletion was induced in newborn PtencKO mice by TM 
injection at P0 and P1, similar SVZ and RMS expansion were consistently detected by 
P10-30 in the absence of other obvious abnormalities (data not shown), although the 
ventral expansion of the SVZ was not detected at this age. 
 
Close examination of the cell morphology in the SVZ revealed that in contrast to 
wild-type control brains in which the SVZ was mainly composed of well-organized 
spindle-like progenitor cells with scant cytoplasm, the expanded SVZ in PtencKO mice 
contained a central region of cells with large round nuclei interspersed with isolated 
progenitor cells, and with clusters of progenitor cells at the edge (Figure 2-3A). This 
expanded region of the SVZ and RMS was composed of Dcx+ and NeuN+ cells which 
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Figure 2-1. The PI3K-mTorc1 pathway was inactive in migrating SVZ 
neuroblasts, but activated in OB neuroblasts. 
IF staining in the SVZ (A and B) and OB (C) of coronal brain sections from 6-month old 
wild-type mice. (A) Pten (green) and Dcx (red) double IF labeling of the SVZ.  Nuclei in 
the SVZ are shown with DAPI (white). Pten was expressed in Dcx+ cells in the SVZ 
(overlay of all channels in the far right panel). (B and C) Mash1 (white), Dcx (red) and p-
S6 (green) triple IF labeling of the SVZ (B) and OB (C), overlay shown in far right 
panels. p-S6 was expressed in Mash1+ transit amplifying cells but not Dcx+ migrating 
neuroblasts in the SVZ (B) while in the OB, a substantial population of Dcx+ type A cells 
expressed p-S6 (C). The white dashed lines in the overlay mark the boundary of the SVZ 
in panels A and B. Scale bar: 20 μm. 
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Figure 2-2. Nestin-CreER targeted neural stem/progenitor cells in the SVZ. 
(A) Schematic diagram of the Nestin-CreER transgene used to target neural 
stem/progenitor cells. (B and C) X-gal staining of sagittal (C and B left and center panels) 
or coronal (B, right panel) sections from Nestin-CreER;Rosa26R-LacZ reporter mice. (D) 
EYFP IF of SVZ from Nestin-CreER;Rosa26R-EYFP reporter mice. The mice were 
injected with vehicle or tamoxifen (TM) daily between P30-32 (B) or between P0-1 (C 
and D) and brains were collected 5 days after the first injection. The most uniform Cre 
activity was induced in the SVZ, RMS and the inner layer of the DG where neural 
stem/progenitors reside. The vast majority of cells in the SVZ were positive for the Cre 
reporters X-gal or EYFP. Cre reporter activity was also detected at low levels in scattered 
cells throughout other brain regions outside of neurogenic niches. This activity outside of 
the neural stem cell niche was more robust when Cre was induced in neonates (C). (E) 
Gfap (red) + EYFP (green), Mash1 (red) + EYFP (green) and Dcx (red) + EYFP (green) 
double IF staining in the SVZ showed overlap of EYFP+ cells with the neural stem cells 
(Gfap+), transit amplifying cells (Mash1+) or neuroblasts (Dcx+) in the far right panels. 
Scale bar: D=100 μm, E=10 μm. Nuclei were visualized with DAPI (blue). 
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Figure 2-3. Postnatal Pten deletion caused ectopic differentiated neurons in an 
expanded SVZ. 
Representative H&E (A), IHC (B-E) and IF staining (F) of the SVZ from matched 
coronal brain sections of mice injected with TM on P30-32 and analyzed more than 70 
days later (n=24). A, D and E upper and lower panels show dorsal and ventral SVZ, 
respectively. (A) H&E staining showed that the PtencKO (cKO) SVZ was expanded 
compared to wild-type (WT). Black box on the cKO panel indicates the expanded SVZ 
region shown at higher magnification on the right panel. Scale bar: left panel=100 μm, 
higher mag panel=10 μm. (B-E) IHC staining of WT and cKO SVZ for Pten (B), p-Akt 
(C), NeuN (D) and Dcx (E). The expanded cKO SVZ was deficient for Pten, strongly 
positive for p-Akt and composed of NeuN+ and Dcx+ cells in contrast to the WT SVZ 
which had only thin layers of Dcx+ cells and lacked NeuN+ cells. In panel D, the NeuN+ 
cells adjacent to the wild-type SVZ were from surrounding striatum and the black line 
marks the edge of the expanded SVZ in cKO brain. Scale bar: B and C=300 μm, D and 
E=100 μm. (F) Mash1 (white), p-S6 (green) and Dcx (red) triple IF labeling of the 
expanded cKO SVZ showed a substantial overlap of p-S6+ and Dcx+ cells in the right 
bottom panel. Scale bar: 20 μm.  
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Figure 2-4. Expansion and ectopic neuronal differentiation in the RMS. 
IHC staining of the RMS from matched coronal brain sections of mice injected with TM 
on P30-32 and analyzed at 6 months of age (A and B) or mice injected with TM on P0-1 
and analyzed at 18 days of age (C). (A) Pten IHC staining of both the WT and cKO RMS 
showed the cKO RMS was expanded and deficient for Pten. The arrow points to a thin 
layer of RMS in the WT whereas the solid black line outlines the cKO RMS. Scale bar: 
200 μm. (B) NeuN IHC staining of both the WT and cKO RMS showed the cKO RMS 
was expanded and composed of NeuN+ cells, whereas the WT RMS was a thin layer 
devoid of NeuN+ cells. Red dashed lines outline both the WT and cKO RMS. Scale bar: 
100 μm. (C) Dcx IHC staining of WT and cKO RMS showed expansion of the cKO RMS 
and formation of projections, whereas in the WT control, DCX expression was in a small 
rim tightly surrounding nuclei. Scale bar: 100 μm. 
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mark migrating neuroblasts and differentiated neurons respectively (Figure 2-3D, E and 
Figure 2-4B, C).  p-S6 staining in the Dcx+ neuroblasts of the PtencKO SVZ (Figure 2-3F) 
shows aberrant activation of the PI3K pathway in contrast to the absence of p-S6 
expression in SVZ neuroblasts in wild-type mice (Figure 2-1B). The Dcx+ cells in the 
expanded SVZ and RMS showed evidence of neuronal differentiation including abnormal 
formation of projections (Figure 2-3E and Figure 2-4C), and Map2 expression, which 
marks dendrites in polarized neurons (Figure 2-5). The expression of Dcx decreased and 
NeuN expression increased in the ectopic cells as mice aged from 150 DPI to 300 DPI 
(data not shown). The expression of mature neuronal markers in Dcx+ cells in the SVZ 
indicates ectopic differentiation of neuroblasts that normally remain undifferentiated until 
they reach the OB.  Furthermore, the ectopic cells also expressed calretinin (Figure 2-5), 
a marker expressed in mature GABAergic interneurons of the OB arising from 
neuroblasts that migrate from the SVZ through the RMS to populate the GCL and the 
periglomerular cell layer of the OB (Kohwi et al. 2005; Kohwi et al. 2007; Alvarez-
Buylla et al. 2008). 
 
Consistent with a failure of migrating neuroblasts to reach the OB, the diameter of 
the terminal RMS at the core of the OB and the cell density in the GCL were markedly 
reduced in PtencKO mice (Figure 2-6 and Figure 2-7A, C). 
 
 
Pten loss did not induce substantial changes in proliferation or survival in the 
expanded PtencKO SVZ 
 
To determine how loss of Pten affected the proliferation in the intact SVZ in vivo, 
we used both Ki67 IHC and short-term BrdU labeling, which gave consistent results 
(Figure 2-8A and data not shown). Because the cell numbers in the SVZ of PtencKO mice 
were increased due to the presence of ectopic post-mitotic differentiated cells, 
considering the percentage of proliferating cells would underestimate the proliferation 
capacity of progenitors in the PtencKO SVZ. Therefore, we counted the absolute numbers 
of Ki67+ cells from matched SVZs of both wild-type and PtencKO mice. There was no 
statistically significant difference in the proliferation rate in the PtencKO SVZ compared to 
control littermates (Figure 2-8A, C). 
 
Activated PI3K signaling can also enhance cell survival, therefore we used active 
caspase3 and TUNEL staining to determine if Pten loss altered apoptosis in the SVZ 
(Figure 2-9A). The endogenous level of apoptosis was very low, and not significantly 
different in wild-type and PtencKO SVZ. Consistent with the resistance of differentiated 
neurons to radiation induced death (Frappart and McKinnon 2008), the expanded portion 
of the PtencKO SVZ containing differentiated neurons as well as the parenchyma 
surrounding the SVZ were resistant to irradiation-induced apoptosis (Figure 2-9B). 
However, the progenitor cells of both wild-type and PtencKO underwent apoptosis 5 hours 
after exposure to 4 Gy of irradiation. Therefore, Pten-deficient neuroblasts did not show 
enhanced survival. 
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Figure 2-5. Ectopic cells in the expanded cKO SVZ expressed markers of mature 
neurons. 
Map2 (A) and Calretinin (B) IHC staining of the SVZ from matched coronal brain 
sections of WT (left) or cKO (right) mice injected with TM on P0-1 and analyzed at 18 
days of age showed strong expression of these markers of neuronal differentiation in the 
expanded cKO SVZ. Scale bar: 100 μm. 
  
28 
 
 
 
 
Figure 2-6. Reduced diameter of the terminal RMS and decreased granule cell 
density in the PtencKO OB. 
Pten IHC staining from matched saggital brain sections of the forebrain (A) or coronal 
brain section of the OB (B and C) from WT and cKO mice injected with TM on P0-1 and 
analyzed at P18 (A and B) or injected with TM on P30-32 and analyzed at 11 months of 
age (C). The cKO SVZ was expanded and deficient for Pten (indicated by arrows in panel 
A). The diameter of the terminal RMS in the cKO OB was diminished (indicated by 
arrowheads in panel A and dashed circles in panel B). The cell density of the GCL in the 
cKO OB was reduced (C). Scale bar: A=500 μm, B=300 μm, C=100 μm. 
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Figure 2-7. PtencKO neuroblasts terminated tangential migration prematurely in 
the SVZ. 
Immuno-staining (A-C) and quantification of BrdU+ cells (D) of matched saggital brain 
sections from WT (left) and cKO (right) mice. Cre activity was induced by tamoxifen 
injection at P0 and 1, BrdU was injected on P4, 5, and 6, and tissue was analyzed at P18. 
(A and B) BrdU IHC staining. (A) In the OB, there were reduced numbers of BrdU+ cells 
in the granule cell layer of the cKO OB compared to WT. (B) In the SVZ, there was a 
significant accumulation of BrdU+ cells in the expanded cKO SVZ. (C) BrdU (red) and 
NeuN (green) double IF labeling of the SVZ from WT and cKO mice showed a 
substantial number of BrdU+ cells in the expanded cKO SVZ were NeuN+, while there 
were no NeuN+ cells in the WT SVZ. Black dashed lines in panel B and white dashed 
lines in panel C mark the boundary of the SVZ. Scale bar: 50 μm. (D) Quantification of 
the granule cell density in OB (OB-Density, p=0.001), BrdU+ cell in the OB (OB- 
BrdU+, p<0.0001) and the percentage of BrdU+ cells in the OB (OB-%BrdU+, p=0.008) 
were all significantly reduced in the GCL of the cKO OB, whereas the total number of 
BrdU+ cells in the cKO SVZ (SVZ-BrdU, p=0.003) was markedly increased (n=4, for 
each genotype). 
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Figure 2-8. mTorc1 inhibition did not affect proliferation or apoptosis in the SVZ. 
Ki67 IHC staining in the SVZ of matched coronal brain sections from WT or cKO mice 
treated with (A) vehicle or (B) rapamycin. Mice were treated with rapamycin or vehicle 
from P8-P31, Cre activity was induced by TM injection at P11 and P12, and tissue was 
analyzed at P31. Scale bar: 100 μm. (C) Quantification of Ki67+ cells in the SVZ showed 
no significant difference between vehicle-treated control and cKO or between vehicle and 
rapamycin-treated cKO. (D) active Caspase 3 IHC staining of the SVZ from vehicle or 
rapamycin-treated cKO mice. There were few active Caspase 3+ cells in either vehicle or 
rapamycin-treated cKO SVZ, and no difference was detected. Scale bar: 100 μm. n=3 
mice per genotype. 
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Figure 2-9. PtencKO SVZ neural progenitors were sensitive to irradiation and 
showed no change in apoptosis compared to control mice. 
(A) TUNEL (top panels) and active caspase 3 (bottom panels) IHC staining of the SVZ in 
matched coronal sections from mice injected with TM on P0-1 and analyzed at 18 days 
old. The endogenous levels of apoptosis were very low in the SVZ and no significant 
difference in apoptosis was detectable between untreated WT and cKO mice. (B) The 
same IHC staining as in panel A. Mice were irradiated with 4 Gy and tissue collected 5 
hrs later. The progenitor cells in both WT and cKO SVZ underwent apoptosis after 
irradiation whereas the parenchyma surrounding the SVZ and the expanded part of the 
cKO SVZ were resistant to irradiation-induced apoptosis. Scale bar: 100 μm. 
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PtencKO neuroblasts terminated tangential migration prematurely in the SVZ and 
RMS 
 
To determine if the ectopic neurons arose from proliferative cells in the SVZ that 
underwent premature termination of tangential migration along the SVZ-RMS-OB, we 
used BrdU birth dating. Pten deletion was induced by TM injection in newborn mice. 
Four days after TM induction, to allow sufficient time for Pten deletion and loss of Pten 
protein, BrdU was injected to label proliferating cells in the SVZ.  As expected, the 
majority of labeled cells in control mice migrated into the GCL of the OB by 15 days 
after the BrdU pulse (Petreanu and Alvarez-Buylla 2002) (Figure 2-7A). In comparison, 
there was a significant accumulation of BrdU+ cells in the expanded SVZ and greatly 
reduced numbers of BrdU+ cells, and reduced granule cell density in the OB GCL in the 
PtencKO mice (Figure 2-7A,B,D). A high percentage of BrdU+ cells in the expanded SVZ 
showed neuronal morphology and expressed NeuN, indicating that the ectopic 
differentiated neurons arose from previously proliferating cells in the SVZ (Figure         
2-7C). In control mice, there were few BrdU+ cells remaining in the SVZ, and none of 
them had neuronal morphology or expressed NeuN. They may correspond to slow-
cycling neural stem cells or local proliferating glia (Figure 2-7C). 
 
 
Inhibition of mTorc1 rescued the SVZ-RMS expansion in PtencKO brain 
 
To determine if inhibition of a downstream effector in the aberrantly activated 
PI3K pathway could prevent the early termination of tangential migration and ectopic 
differentiation of PtencKO neuroblasts in the SVZ, we treated the mice with rapamycin, an 
inhibitor of mTorc1 activity. We previously showed that rapamycin required several days 
of administration to maximally block mTorc1 signaling in brain (Kwon et al. 2003). 
Therefore, we pre-treated the mice daily with rapamycin for three days, then induced the 
deletion of Pten with TM at P11-12 and continued rapamycin treatment until P31. 
Rapamycin treatment completely prevented the expansion of the SVZ in PtencKO mice 
(Figure 2-10A), although the SVZ remained Pten-null in rapamycin treated mice (Figure 
2-10B). Rapamycin selectively blocked mTorc1 activity, as shown by lack of p-S6, a 
downstream indicator of mTorc1 activity (Figure 2-10C) without altering levels of p-Akt 
in the Pten-deficient SVZ (Figure 2-10D). Neither apoptosis nor proliferation was 
affected by rapamycin treatment (Figure 2-8). 
 
 
Ex vivo time-lapse live imaging showed PtencKO neuroblasts had normal directional 
migration with increased speed 
 
To understand how Pten loss affected the movement of tangentially migrating 
neuroblasts, we used time-lapse live imaging on acute brain slices. We transfected the 
expression construct pCAG-Cre into the SVZ by in vivo electroporation at age P2 and 
visualized transfected cells by expression of the EYFP Cre reporter in R26R-
EYFP;Ptenwt/wt (wild-type) or R26R-EYFP;PtenloxP/loxP (PtencKO) mice. Neuroblast 
migration was imaged with two-photon microscopy at the “elbow” of the RMS, at the 
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Figure 2-10. mTorc1 inhibition rescued the expansion of PtencKO SVZ. 
Representative IHC staining for Dcx (A), Pten (B), pS6 (C), and pAkt (D) in the SVZ of 
matched coronal brain sections from vehicle or rapamycin treated WT or cKO mice. 
Mice were treated with rapamycin or vehicle from P8-P31, Cre activity was induced by 
TM injection at P11 and P12, and tissue was analyzed at P31. Rapamycin completely 
rescued the enlargement of cKO SVZ to restore the size and morphology seen in WT 
mice (n=4 in each group). The SVZ of rapamycin treated cKO mice remained Pten-null 
(B) and continued to show elevated pAkt (D), but showed suppression of pS6 (C), a 
downstream indicator of mTorc1 activity. Scale bar: 50 μm. 
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region where the RMS curves from ventral towards rostral migration halfway between 
the SVZ and the OB (see Figure 2-11 C for the location) at age P19-20. The majority of 
EYFP+ cells in the wild-type RMS showed a bipolar morphology and migrated 
effectively.  In contrast, there were two distinct populations of EYFP+ cells in the 
PtencKO RMS (Figure 2-12A). One population maintained bipolar morphology and 
migrated normally as in the wild-type control, while another population lost polarity and 
showed only local non-directional movement. Interestingly, the cells that had stopped 
directional migration showed active spontaneous membrane ruffling, which distinguished 
them from completely static cells seen at very low frequency in both the wild-type and 
PtencKO RMS (Supplementary movies A-1 and A-2). The average speed of all EYFP+ 
cells in the PtencKO RMS (mean: 0.0096 μm/s) was significantly slower than that of the 
wild-type (mean: 0.0143 μm/s) (p<10-19). However, the average speed of bipolar 
migrating neuroblasts in the PtencKO RMS (mean: 0.0173 μm/s) were slightly but 
significantly faster than the wild-type (mean: 0.0156 μm/s) (p=0.006) (Figure 2-12B, C). 
The PtencKO bipolar migrating neuroblasts moved effectively in the appropriate caudal to 
rostral direction, as their endpoint speeds, a representation of directional movement, were 
slightly but significantly greater than the wild-type (mean 0.0145 μm/s and 0.0131 μm/s, 
respectively (p=0.047). Accordingly, a substantial number of Pten-deficient neuroblasts 
were able to migrate to the OB (Figure 2-11). Both the EYFP+ bipolar and round non-
polar cells in the RMS expressed Dcx, indicating that they were migrating neuroblasts or 
neuroblasts that stopped migration recently (Figure 2-13). These data indicate that Pten-
deficient neuroblasts do not have an intrinsic defect that compromises migration. 
 
 
Discussion 
 
 
Pten function in neuronal migration and differentiation 
 
Multiple conditional knock-out models have shown that Pten deletion during 
development results in incomplete neuronal migration causing disruption of the laminar 
structure in cerebral cortex and cerebellum. The accumulation of ectopic differentiated 
PtencKO neurons in the SVZ and RMS observed in the present study is consistent with 
defects in tangential migration, similar to the failure of radial glia-guided migration in the 
cerebral cortex and cerebellum observed in previous models (Backman et al. 2001; 
Groszer et al. 2001; Kwon et al. 2001; Marino et al. 2002; Yue et al. 2005). SVZ 
expansion associated with premature termination of tangential migration was also 
observed in mouse models knocking out PSA-NCAM (Tomasiewicz et al. 1993; Ono et 
al. 1994), serum response factor (Alberti et al. 2005), ApoER2/VLDL or Dab1 (Andrade 
et al. 2007), which might suggest an epistatic relationship between them and Pten. 
 
PTEN and the PI3K-Akt-mTorc1 pathway have been implicated in cell migration 
regulation in multiple contexts. Mechanistically, this has been mostly clearly 
demonstrated in Dictyostelium discoideum where subcellular localization of Pten and 
PI3K to the trailing and leading edge of the cell, respectively, established a PIP3 gradient 
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Figure 2-11. EYFP+ cells in the PtencKO RMS and OB were Pten-null. 
Ptenflox/flox (cKO) mice carrying a ROSA-lox-STOP-lox-EYFP allele were transfected 
with Cre by in vivo electroporation as described for Figure 2-12.  EYFP and Dcx double 
IF labeling of the cKO RMS elbow from littermate mice electroporated at the same time 
as those used for in vivo time lapse imaging showed that both the arrested non-polar cells 
(arrowheads) and the elongated migrating cells (arrow) in the cKO RMS were positive 
for Dcx (overlay in the bottom right panel). Scale bar: 100 μm. 
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Figure 2-12. Ex vivo time-lapse live imaging showed PtencKO neuroblasts had 
normal directional migration with faster speed. 
(A) Representative static EYFP images corresponding to the time-lapse migration movies 
from the RMS (supplemental).  A Cre expression construct was transfected by in vivo 
electroporation at P2 into the SVZ of WT or Ptenflox/flox (cKO) mice carrying a ROSA-
lox-STOP-lox-EYFP allele. Acute brain slices were prepared at P19-20, and cells in 
which Cre-mediated recombination occurred were visualized by EYFP reporter 
expression using two-photon microscopy. The vast majority of WT neuroblasts had 
bipolar morphology and were migrating. There were two distinct populations of PtencKO 
(cKO) neuroblasts; cells with elongated bipolar morphology and normal migration 
(indicated by arrowheads), and cells with large rounded morphology that showed only 
local non-directional movement (indicated by arrows). Scale bar: 50 μm. (B and C) 
Quantification and histogram of average speeds for bipolar migrating EYFP+ cells (B) or 
all EFYP+ cells (C) from WT (red bars) and cKO RMS (green bars). n=3 mice per 
genotype.  
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Figure 2-13. The arrested EYFP+ cells in the PtencKO RMS were in the neuronal 
lineage. 
Ptenflox/flox (cKO) mice carrying a ROSA-lox-STOP-lox-EYFP allele were transfected 
with Cre by in vivo electroporation as described for Figure 2-12.  EYFP and Dcx double 
IF labeling of the cKO RMS elbow from littermate mice electroporated at the same time 
as those used for in vivo time lapse imaging showed that both the arrested non-polar cells 
(arrowheads) and the elongated migrating cells (arrow) in the cKO RMS were positive 
for Dcx (overlay in the bottom right panel). Scale bar: 100 μm. 
  
39 
 
that was required for directional migration and chemotaxis (Funamoto et al. 2002; Iijima 
and Devreotes 2002). Deletion of the Akt homolog PkbA, rescued the cytokinesis and 
chemotaxis defects in Pten deficient Dictyostelium (Tang et al. 2011). In mammalian 
cells, the PI3K pathway can regulate cell motility and migration through Akt activation as 
well as through Akt-independent mechanisms such as RAC1/CDC42 signaling (Kolsch et 
al. 2008). In addition, overexpression of wild-type PTEN inhibited migration of human 
glioma cell lines in an in vitro wound healing assay, and this effect was dependent on the 
protein phosphatase activity of PTEN independent of PI3K signaling (Raftopoulou et al. 
2004). 
 
Unexpectedly, we found that Pten-null neuroblasts in the RMS had normal 
directional movement with faster speed using two-photon time-lapse microscopy of ex 
vivo slice cultures that maintain the physiological context for neuronal migration. 
Postnatal deletion of Pten divided the RMS neuroblasts into two distinct populations; one 
subset maintained their bipolar morphology and had normal directional migration and the 
other population lost polarity and stopped migration. This non-polar morphology, in 
association with increased frequency of spontaneous protrusions of the plasma  
membrane, was reminiscent of Pten-null Dictyostelium. However, the population of 
PtencKO neuroblasts that maintained bipolar morphology continued moving normally, 
demonstrating that Pten was not required for directional migration.  This is consistent 
with the observation that some Pten-null cells reach the OB in PtencKO mice. A previous 
study in which Pten was deleted in Gfap-expressing neural stem cells also showed that 
Pten-deficient neurons were capable of reaching the olfactory bulb.  This study also noted 
an expansion of Dcx+ cells in the SVZ and RMS, although they did not analyze 
expression of mature neuronal markers in these cells (Gregorian et al. 2009). Postnatal 
deletion of Pten in cerebellar granule neurons also showed that a subset of Pten-null 
granule cells migrated to the proper position in the internal granule layer, while many 
were ectopically located in the molecular layer and at the pial surface (Backman et al. 
2001; Kwon et al. 2001).  Failed migration of Pten-deficient cerebellar neurons has been 
suggested to be secondary to defects in the glia guiding their migration (Yue et al. 2005). 
However, the in vivo electroporation approach used in the present study targeted small 
numbers of cells and identified stationary Dcx+ neuroblasts without Cre-mediated 
deletion in other surrounding cell types.  The results in the RMS are consistent with cell 
autonomous defects leading to ectopic positioning.  
 
Normal directional migration of Pten-null neuroblasts is consistent with the 
finding that directional chemotaxis can still occur in Dictyostelium in the absence of a 
PIP3 gradient (Hoeller and Kay 2007). Additionally, several studies showed that Pten was 
not essential in directional migration and chemotaxis of mammalian leukocytes (Lacalle 
et al. 2004; Ferguson et al. 2007; Nishio et al. 2007; Subramanian et al. 2007; Heit et al. 
2008). Pten deficient neutrophils showed an increased migration speed similar to the 
neuroblasts in the our study (Subramanian et al. 2007). Thus, there are likely context-
dependent signals driving the effect of Pten and PI3K signaling on migration. 
 
Pten-deficient neuroblasts demonstrate an “all or none” phenotype of normal 
directional migration or abnormal morphology associated with arrested migration. Taken 
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together, the data suggest that the ectopic localization of neurons is more likely attributed 
to premature differentiation and secondary loss of migration ability rather than intrinsic 
defects in migration. Indeed, the PI3K-Akt-mTorc1 pathway has been shown to play an 
important role in several crucial neuronal differentiation processes including neuronal 
polarity, axon guidance, dendrite arborization and spine morphogenesis (Campbell and 
Holt 2001; Jaworski et al. 2005; Kumar et al. 2005; Tavazoie et al. 2005; Chadborn et al. 
2006; Kwon et al. 2006; Wildonger et al. 2008; Chow et al. 2009).  
 
 
PI3K-Akt-mTorc1 pathway regulation in the SVZ-RMS-OB 
 
The PI3K-Akt-mTorc1 pathway is dynamically regulated through the different 
developmental stages of neuronal lineage along the SVZ-RMS-OB. From birth in the 
SVZ to differentiation and integration into the local circuit of the OB, neural stem cells 
progress in phases to transit amplifying progenitors, migrating neuroblasts and ultimately 
terminally differentiated mature neurons. Accordingly, cell signaling pathways must be 
modulated to meet the varying requirements of these differentiation states or to induce 
transition between consecutive phases. In this study, we found that the PI3K-Akt-mTorc1 
pathway is active in the transit amplifying cells and inactive in the migrating neuroblasts 
until activated again in the OB. Consistent with these findings, previous studies also 
found high expression of Egfr, a potent PI3K-Akt-mTorc1 pathway activating receptor, 
in the transit amplifying progenitors but not in the migrating neuroblasts in the SVZ.  The 
abundant free ribosomes found in transit amplifying progenitors is consistent with 
activation of mTorc1 signaling (Doetsch et al. 2002; Kim et al. 2009; Kokovay et al. 
2010).  
 
Upregulation of the PI3K-Akt-mTorc1 pathway may act to drive proliferation of 
transit amplifying progenitors, while inactivation of PI3K-Akt-mTorc1 signaling through 
Pten expression may play a role in the transition to migrating neuroblasts which exit the 
cell cycle. In support of this theory, enhanced Egfr signaling in vivo expands the 
proliferative pool, arrests neuronal production (Doetsch et al. 2002; Aguirre et al. 2010) 
and negatively regulates migration in the SVZ (Kim et al. 2009).  In our system, Pten 
deletion did not have a substantial effect on proliferation.  The magnitude of PI3K 
signaling is a balance between the level of upstream activation of the pathway and the 
negative regulatory activity of Pten. In other studies, Pten loss has been shown to increase 
proliferation of neural stem cells in vitro, and during other developmental stages in the 
SVZ (Groszer et al. 2001; Gregorian et al. 2009).  The proliferation consequences 
downstream of Pten loss are likely influenced by the extent of upstream activation of 
PI3K driven by the growth factor environment at different developmental stages. 
 
In wild-type RMS, the PI3K-Akt-mTorc1 pathway is not activated in Dcx+ cells 
until they reach the OB, which correlates well with the time when they begin further 
differentiation. This suggests that the PI3K-Akt-mTorc1 pathway might be involved in 
the transition from a migratory neuroblast to a differentiating neuron in response to local 
environmental cues. In the absence of Pten, premature activation of PI3K signaling in 
neuroblasts in the RMS likely triggers precocious differentiation resulting in ectopic 
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positioning. Inhibition of mTorc1 activity effectively rescued ectopic differentiation of 
neuroblasts and prevented the expansion of the SVZ and RMS, further supporting 
premature differentiation as a primary cause instead of a defect in the intrinsic migratory 
machinery. mTorc1 modulates protein synthesis and cell growth and plays an important 
role in neuronal differentiation processes (Campbell and Holt 2001; Jaworski et al. 2005; 
Kumar et al. 2005; Tavazoie et al. 2005; Kwon et al. 2006; Wildonger et al. 2008; Chow 
et al. 2009). The rapamycin-mediated rescue of ectopic neurons in PtencKO brains 
occurred in the absence of proliferation effects. This could be explained by the recent 
finding that rapamycin potently inhibits S6K activity, but inefficiently and transiently 
inhibits 4EBP1 phosphorylation (Choo et al. 2008; Dowling et al. 2010). 4EBP1, 
independent of S6K, controls mTorc1-mediated cell proliferation (Dowling et al. 2010). 
Taken together, our results along with previous studies, suggest that proper temporal and 
spatial regulation of the PI3K-Akt-mTorc1 pathway plays an important role in regulating 
the appropriate timing and positioning for neuronal differentiation, but is not required for 
directional tangential neuronal migration. 
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CHAPTER 3.    CO-DELETION OF PTEN AND TRP53 SYNERGIZES IN 
GENERATING MEDULLOBLASTOMA WITH A GROWTH PATTERN 
CENTERING AROUND BLOOD VESSELS 
 
 
Introduction 
 
Cells in the cerebellum arise from two germinal zones: the ventricular zone and 
the EGL. The ventricular zone is the germinal neuroepithelium during embryogenesis and 
generates deep cerebellar nuclei and Purkinje cells as well as other GABAergic neurons 
in the cerebellum (Goldowitz and Hamre 1998). Ptf1a, a bHLH transcription factor, is 
required for the GABAergic neuron specification in the ventricular zone and loss of 
function resulted in complete loss of cerebellar GABAergic neurons (Sellick et al. 2004; 
Hoshino et al. 2005). 
 
At birth, the ventricular germinal neuroepithelium disappears and proliferative 
precursors in the rhombic lip emigrate along the pial surface and form the EGL (Carletti 
and Rossi 2008). The EGL proliferates most during early postnatal days and produces all 
the internal granule cells (Wang and Zoghbi 2001). Multiple cell signaling pathways, for 
instance, cyclinD2 (Huard et al. 1999), p27 (Miyazawa et al. 2000), Shh (Dahmane and 
Ruiz i Altaba 1999), N-myc (Knoepfler et al. 2002), PI3Ks (Kenney et al. 2004) and 
Math1 (Ben-Arie et al. 1997) are crucial for cerebellar granule cell development among 
which the Shh signaling pathway is one of the best characterized. Shh, expressed by 
Purkinje cells, binds to its receptor, Ptch1, on granule cell precursors in the EGL, 
promotes proliferation and prevents their differentiation (Wallace 1999; Wechsler-Reya 
and Scott 1999). Unrestricted Shh signaling caused by Ptch1 mutation leads to 
medulloblastoma in both human and mouse (Goodrich et al. 1997). Pten is also required 
for the normal development of the cerebellum. Deletion of Pten in the granule progenitors 
in the EGL lead to ectopic positioning and hypertrophy of cerebellar granule cells 
(Backman et al. 2001; Kwon et al. 2001; Marino et al. 2002). 
 
Aside from the two well characterized germinal zones in the developing 
cerebellum, multipotent neural stem cells have been isolated from the cerebellum 
postnatally and are thought to be located in the white matter tracts (Lee et al. 2005) which 
might arise from embryonic ventricular zone and emigrate into the white matter tracts 
(Zhang and Goldman 1996). The identity and function of this pool of neural 
stem/progenitor cells are largely unknown. 
 
Medulloblastoma is a collection of clinically and molecularly heterogeneous 
diseases and can be divided into several subtypes (Thompson et al. 2006; Kool et al. 
2008; Northcott et al. 2010; Cho et al. 2011). The subtype of medulloblastoma harboring 
mutations in Shh pathway including Ptch1 and Sufu is thought to originate from the EGL 
precursors and is supported by Ptch1 knock-out mouse models (Schuller et al. 2008; 
Yang et al. 2008). The Wnt subtype of medulloblastoma is likely to develop from cells of 
the dorsal brainstem outside of cerebellum (Gibson et al. 2010). Cells of origin for other 
medulloblastoma subtypes are still unknown. 
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Cancer initiating cells, or cancer stem cells, are the subpopulation in the primary 
tumor that are capable of self-renewing, differentiating and regenerating its original 
tumor when transplanted in vivo. Cancer initiating cells have now been isolated from 
human cancers of the blood, breast, brain, skin, bone, and prostate (Ward and Dirks 
2007). They are hypothesized to sustain tumor growth and be responsible for the relapse 
and metastasis. Cancer initiating cells could also be isolated from human 
medulloblastomas (Singh et al. 2003; Singh et al. 2004) and were shown to reside in a 
perivascular niche (Calabrese et al. 2007). The perivascular cell population were found to 
account for the re-growth of Ptch1-mutant medulloblastoma tumor after irradiation-
induced apoptosis (Hambardzumyan et al. 2008). However, it is unknown whether there 
is a perivascular population of cells in the wild-type brain which is susceptible to 
oncogenic transformation and whether they could serve as cells of origin for 
medulloblastoma. 
 
In addition to Shh and Wnt pathways, PI3K is another pathway aberrantly 
regulated in human medulloblastoma. Human medulloblastomas are found to over-
express RTKs such as ERBB2 (Hernan et al. 2003) and PDGFRB (MacDonald et al. 
2001; Gilbertson and Clifford 2003). Proliferation of human medulloblastoma cells are 
dependent on activation of PI3K/AKT signaling perhaps caused by reduction of PTEN 
expression (Hartmann et al. 2006). Recent whole genome sequencing of 88 human 
medulloblastomas found PTEN mutations occur together with either PTCH1 or TP53 
mutations (Parsons et al. 2011) which suggests a cooperative effect between PI3K and 
Ptch1 pathways. Mouse studies have also shown the synergistic effects of Ptch1 loss with 
Igf2, PI3K or Akt in generating medulloblastomas (Hahn et al. 2000; Rao et al. 2004; 
Riobo et al. 2006). However, the exact cooperative effects need further investigation. 
 
In the present study, we inactivated Pten in the neural stem/progenitor cells at 
birth using a Nestin (a marker for the neural stem/progenitor cells) promoter driven 
CreER transgenic mouse and revealed a novel perivascular proliferative niche in the 
cerebellum. Co-deletion of Pten and Trp53 synergized in generating medulloblastoma 
with a growth pattern centering around blood vessels and extensive neuronal 
differentiation suggesting a potential new cell of origin for medulloblastoma. 
 
 
Experimental Procedures 
 
 
Mice 
 
For Cre activity mapping, Nestin-CreERT2 transgenic mice were bred with R26R-
EYFP (Srinivas et al. 2001) mice to generate Nestin-CreERT2;R26R-EYFP mice. Cre 
activities were detected by EYFP IF staining on frozen tissue sections. Nestin-
CreERT2;PtenloxP/loxP (PtencKO) mice were generated by crossing Nestin-CreERT2 mice to 
PtenloxP mice (Suzuki et al. 2001), a gift from Tak Mak (University of Toronto, Toronto). 
Nestin-CreERT2;PtenloxP/loxP;Trp53loxP/loxP (PtencKO;Trp53cKO) mice were generated by 
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breeding Nestin-CreERT2;PtenloxP/loxP with Trp53loxP mice (Jonkers et al. 2001). For all 
analyses including Nestin-CreERT2, the transgene was hemizygous to avoid possible 
variation from transgene dosage. All procedures were reviewed and approved by the 
Animal Care and Use Committee at St. Jude Children's Research Hospital. 
 
 
Genotyping polymerase chain reaction assays 
 
PCR was used to genotype mice. Primers used were: Cre, forward primer: 
5’AGCGATCGCTGCCAGGAT; reverse primer: 5’ACCAGCGTTTTCGTTCTGCC; 
expected product: 157 base pairs. Pten, forward primer: 
5’TTATCTGGATCAACTTTGGGCC; reverse primer: 
5’TCCCACCAATGAACAAACAGT; expected products: 146 (wild-type) and 244   
(loxP) base pairs. Trp53, forward primer: 5’CACAAAAACAGGTTAAACCCAG; 
reverse primer: 5’AGCACATAGGAGGCAGAGAC; expected products: 288 (wild-type) 
and 370 (loxP) base pairs. 
 
 
Induction of Cre activity 
 
TM (Sigma) was dissolved at 5 mg/ml at 37°C in corn oil (Sigma) and sterilized 
by filtering and stored at 4°C in the dark for up to 10 days. Pups were injected daily with 
3 mg/40g TM i.p. from P0-1. An equivalent volume of sterile filtered corn oil alone was 
used for vehicle injections. Two injections in the same mouse were separated by 24  
hours. 
 
 
Immunohistochemistry and immunofluorescence 
 
Mice were anesthetized and perfused transcardially with 1x PBS followed by 4% 
PFA in PBS. Following dissection, tissues were post-fixed overnight in 4% PFA in PBS 
at 4°C, and then equilibrated in 25% sucrose in PBS for an additional 24 hours at 4°C. 
Tissues were embedded in TBS embedding media (Triangle Biomedical Sciences) on dry 
ice and cut into 12 μm thick cryosections. Tissue slides were equilibrated at room 
temperature for 20 minutes then washed three times in PBS prior to staining. For paraffin 
sections, mice were processed the same way as above. Following perfusion, tissues were 
post-fixed for an additional 24 hours in 4% PFA, embedded in paraffin, and cut into 5 μm 
sections. Primary antibodies used for immunostaining were against GFP (1:1000, 
Invitrogen A6455; 1:2000, Abcam #13970), Pten (1:100, Cell Signaling #9559), p-Akt 
S473 (1:50, Cell Signaling #9271), Gfap (1:200, Sigma G3893), Ki67 (1:5000, 
Novocastra NCL-Ki67p), CD34 (1:100, BD Pharmingen #553731), CD45 (1:400, BD 
Pharmingen #553076), CD133 (1:100, eBioscience #12-1331) and Nestin (1:100, 
Chemicon MAB353). For IHC, microwave antigen retrieval was performed for all 
antibodies and biotinylated secondary antibodies were used in conjunction with 
horseradish peroxidase-conjugated streptavidin (Elite ABC, Vector Laboratories). Color 
development was conducted with substrates NovaRed, DAB or VIP (Vector  
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Laboratories) and counterstaining with hematoxylin or methyl green (Vector 
Laboratories), respectively. For IF, Alexa Fluor 488, 647 (Invitrogen) and cyanine 3, 5 
(Jackson ImmunoResearch) conjugated secondary antibodies were employed along with 
Vectashield mounting media containing DAPI (Vector Laboratories). 
 
 
Array comparative genomic hybridization analysis 
 
Genomic DNA was prepared by scraping tumor tissues from multiple 
deparaffinized sections, followed by Proteinase K-digestion and phenol-chloroform 
extraction. DNA quality was verified by gel electrophoresis. Control DNA was isolated 
from the spleens and livers of wild-type FVB mice. A total of 20 Pten; p53 double cKO 
tumors were analyzed using the Roswell Park Cancer Institute (RPCI) 6.5K mouse BAC 
array comparative genomic hybridization (aCGH). 
 
 
Fluorescent in situ hybridization analysis 
 
Fluorescent in situ hybridization (FISH) analysis was performed on paraffin 
sections by the St. Jude Cancer Center Core Cytogenetic Laboratory. Purified DNA from 
a BAC clone (RP24-70J8 cl.1) containing the murine Ptch1 locus was labeled with 
digoxigenin-11-dUTP (Roche Molecular Biochemicals) by nick translation. The murine 
Ptch1 clone is known to localize to mouse chromosome band 13B3 so a biotinylated 
mouse 13 control clone (RP24-386H1O) was used as an internal control for the FISH 
assays. The Ptch1 clone and the chromosome 13 control clone were combined with 
sheared mouse DNA and hybridized in a solution containing 50% formamide, 10% 
dextran sulfate, and 2X SSC to the deparaffinized and pepsin treated slides. Specific 
hybridization signals were detected by incubating the hybridized slides in fluorescein 
labeled anti-digoxigenin (Roche Molecular Biochemicals) and Texas red avidin (Vector 
Laboratories Inc). The cells were then stained with DAPI and analyzed. A total of 200 
interphase cells were scored from each sample for the number of green (70J8) and red 
signals (386HI0) per cell. 
 
 
Quantitative real-time polymerase chain reaction assay 
 
The same genomic DNA extracted for aCGH assay was used for real-time PCR 
analysis. The primer/probe set spanning Ptch1 exon 2 was used, forward primer 
Ptch1ex2-SDS-F (5′-GGCTACTGGCCGGAAAGC), reverse primer Ptch1ex2-SDS-R 
(5′-GAATGTAACAACCCAGTTTAAATAAGAGTCT) and Taqman probe Ptch1ex2-
SDS-F (5′-CCGCTGTGGCTGAGAGCGAAGTTTC). Gapdh (located on mouse 
chromosome 6) was used as internal standards to normalize the data. Four nanograms of 
DNA from tumor samples or Gapdh DNA were amplified in TaqMan Fast Universal 
PCR Master Mix (Applied Biosystems) using a 7900HT Fast Real-Time PCR system 
(Applied Biosystems) (95°C for 20 seconds, then 40 cycles of 95°C for 5 seconds and 
60°C for 30 seconds). Standard curve was generated from three-fold serial dilutions of 
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Gapdh DNA. Quantitative real-time PCR for each sample was performed in triplicate and 
means were reported. The result of real-time PCR was analyzed with SDS ver2.3 
software (Applied Biosystems). 
 
 
Ptch1 sequence analysis 
 
Ptch1 sequencing analysis was done as describe by Lee et al. (2006b). Total RNA 
was extracted from snap-frozen medulloblastoma samples using Trizol (Invitrogen). 
cDNA was synthesized from tumor RNA by reverse transcription using random hexamer 
primers and SuperScript II Reverse Transcriptase (Invitrogen). After cDNA synthesis, 
two rounds of PCR amplification were performed to obtain sufficient Ptch1 products for 
sequencing. The first round of PCR was done with forward primer Ptch1-14 (5′-
ACGCGCAATGTGGCAATGGAAGGC) and reverse primer Ptch1-R1 (5′-
GAAGCGGCCGCTTCAGATTTTAATTACCC) to amplify a full-length Ptch1. 
Subsequently, the PCR products were further amplified with following five different sets 
of primers whose products overlapped each other and spanned a full-length of Ptch1. Set 
A: forward primer Ptch1-F (5′-ATGGCCTCGGCTGGTAACG) and reverse primer 
Ptch1-1 (5′-AAGGCCGGTCCATGTACCCATGGC); set B: forward primer Ptch1-2 (5′-
GCTTAATCATTACACCTTTGGACTGC) and reverse primer Ptch1-6 (5′-
AAAGGAGCATAGTGCTTCTCTGC); set C: forward primer Ptch1-5 (5′-
TTGAGCCACAGGCCTACACAGAGC) and reverse primer Ptch1-8 (5′-
GTCTGAGGTGTCTCGTAGGCCG), set D; forward primer Ptch1-7 (5′ 
TGGGAAACTGGGAGGATCATGC) and reverse primer Ptch1-10 (5′ 
GCTCAGGCGAAGGAGTGGGCAGTCG); and set E: forward primer Ptch1-9 (5′-
GTGGAGTTCACCGTCCACGTGGC) and reverse primer Ptch1-R2 (5′-
GAAGCGGCCGCTCAGTTGGAGCTGCTCCCCCACGGC) . The PCR products were 
sequenced by a routine Big Dye Terminator (v.3) Chemistry approach on Applied 
Biosystem 3700 DNA analyzer. 
 
 
Results 
 
 
Nestin-CreERT2 targets cerebellum at birth 
 
Nestin-CreERT2;R26R-LacZ or Nestin-CreERT2;R26R-EYFP mice were injected 
with TM to map the Cre activity at birth when brain is still undergoing active 
development. Consistent with the fact that developing brain has stronger expression of 
Nestin (Lendahl et al. 1990) and more common neural stem/progenitors, Cre activities in 
Nestin-CreERT2 lines were more robust in immature brain with strongest activities in the 
neural stem/progenitor cell niches including the SVZ and the EGL of cerebellum (Figure 
2-2C). The bulk of cerebellum develops postnatally, so Nestin-CreERT2 could target the 
cerebellum including the EGL, IGL and white matter tracts very effectively with TM 
induction at birth (Figure 3-1). Littermate control with vehicle injection showed very low 
level of TM-independent leaky Cre activity (Figure 3-1).  
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Figure 3-1. Nestin-CreERT2 targets cerebellum at birth. 
EYFP IF staining of the cerebellum from mice induced with vehicle or TM from P0-1. 
Tissue was harvested at P5. Strong EYFP signals were noticed in the EGL, IGL and 
white matter tract of cerebellum in the TM-induced mice whereas mice with vehicle 
induction had only very low level of EYFP. Scale bar: 100 μm. 
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Deletion of Pten at birth resulted in disorganization and hypertrophy of cerebellum 
which mimics human Lhermitte-Duclos disease 
 
We induced the deletion of Pten in the Nestin-CreERT2;PtenloxP/loxP (PtencKO) 
neonate mice to see the effect of broad Pten loss on a developing brain. The PtencKO mice 
did not show obvious abnormalities until 2-3 months of age when the animals started to 
exhibit lethargy, progressive enlargement of the skull and progressive neurological 
abnormalities including ataxia and seizure. One hundred percent of the mice (16/16) 
induced at birth were affected whereas none of the un-induced PtencKO mice or TM-
treated wild-type littermates showed these deficits. Animals had to be euthanized due to 
severe ataxia and brain hypertrophy with a median survival of 153 days (Figure 3-2C). In 
addition to the dramatic expansion of the SVZ and RMS described in Chapter 2, brains 
from PtencKO mice induced with TM at birth showed profound hydrocephalus and 
dramatic increases in overall sizes especially in cerebellum (Figure 3-2A). The foliation 
was visible but the organization of cell layers was disrupted in the cerebellum. The 
molecular layer (ML) was dramatically thickened with many ectopic granule cells 
deficient of Pten staining. The majority of Purkinje cells were positive for Pten staining 
but the normal monolayer structure was not nicely formed. The IGL was thinner than 
wild-type control and composed of both Pten positive and negative granule cells (Figure 
3-2B). The size of the Pten-deficient granule cells is larger than the Pten positive granule 
cells in aging mice (not shown). All these abnormalities mimic human Lhermitte-Duclos 
disease and are in agreement with previous findings but in a more severe manifestation 
(Backman et al. 2001; Kwon et al. 2001). 
 
 
Pten inactivation at birth revealed novel ectopic perivascular proliferative niches in 
the cerebellum 
 
In addition to the cerebellar disorganization and hypertrophy, we identified 
multiple perivascular proliferative niches in the cerebellum (20/24 mice) when deleting 
Pten in neonatal neural stem/progenitor cells at birth, which have never been observed 
before in previous PtencKO mouse models (Backman et al. 2001; Kwon et al. 2001; Fraser 
et al. 2004). The perivascular hyperplastic lesions were observed as early as 3 months of 
age but were not found in 30-day-old mice (data not shown). These hyperplastic lesions 
grew surrounding CD34+ blood vessels and had high percentage of Ki67+ cells (Figure 
3-3). The perivascular proliferative lesions varied in their sizes from as few as several 
cells to hundreds of cells. They were distributed throughout cerebellum but were more 
frequently found in anterior and lateral cerebellar lobules and in areas around the pia 
between lobules (data not shown). They are not infiltrating inflammatory cells (CD45-) 
but have a progenitor-like appearance. They tend to express Nestin and CD133 which 
mark neural stem/progenitor cells or brain tumor initiating cells (Lendahl et al. 1990; 
Singh et al. 2003; Singh et al. 2004; Coskun et al. 2008) as well as Gfap that labels neural 
stem cells in the SVZ (Doetsch et al. 1999)(Figure 3-3). These perivascular precursor-like 
cells are Pten null and p-Akt positive indicating that they derived from cells that 
underwent Cre-mediated recombination (Figure 3-3). However, these perivascular  
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Figure 3-2. Deletion of Pten at birth resulted in disorganization and hypertrophy 
of cerebellum. 
Representitive H&E (A) and Pten (B) IHC staining of the cerebella from mice induced 
with TM at birth. (A) H&E staining of the wild-type (WT) and PtencKO (cKO) brains 
showed dramatic hypertrophy of the PtencKO brain. (B) Pten IHC staining of the WT and 
cKO brains showed disrupted organization of the cerebellum and ectopic Pten-deficient 
granule cells in the molecular layer in the PtencKO brain. Scale bar: 200 μm. (C) Kaplan-
Meier survival curves shows PtencKO mice had a median morbidity age of 153 days due 
to macrocephaly and hydrocephaly (brown curve). 
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Figure 3-3. Pten inactivation at birth reveals novel perivascular proliferative 
niches in the cerebellum. 
IHC staining as indicated of the cerebella from mice induced with TM at birth. The 
perivascular lesion growing surrounding CD34+ blood vessels has a high percentage of 
Ki67+ cells. The perivascular cells are negative for CD45, a marker for leukocytes, but 
have progenitor-like appearance. They tend to express Nestin, CD133 and Gfap 
indicating their neural stem/progenitor identity. These perivascular precursor-like cells 
are Pten null and positive for p-Akt indicating they are derived from cells that underwent 
re-mediated recombination. Scale bar: CD45, Pten and p-Akt=100 μm, others=50 μm. 
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hyperplastic lesions were never found to develop into full-blown tumors in mice up to 10 
months of age. 
 
 
Co-deletion of Pten and Trp53 at birth resulted in medulloblastoma with unusual 
vascularization 
 
Since TP53 is one of the most frequent mutations in several common primary 
human brain tumors (Frank et al. 2004; Parsons et al. 2008; TCGA 2008; Parsons et al. 
2011), we asked whether or not loss of Pten during early postnatal development would 
cooperate with Trp53 deficiency in generating full-blown cerebellar malignancy. Nestin-
CreERT2;PtenloxP/loxP mice were bred to Trp53loxP mice to generate Nestin-
CreERT2;PtenloxP/loxP;Trp53loxP/loxP (dKO) mice and induced at birth. All of the dKO mice 
(26/26) developed cerebellar tumors which resemble human medulloblastoma with a 
median tumor onset of 63 days of age and Nestin-CreERT2;PtenloxP/+;Trp53loxP/loxP mice 
(22/25) succumbed to the same tumor with a one-month delay in onset compared to dKO 
mice (Figure 3-4D and data not shown). All the dKO medulloblastomas manifested as 
highly cellular neoplasms of classic medulloblastoma pathology composed of small blue 
cells with two striking features, high vascularization and perivascular clustering of tumor 
cells, which distinguish this tumor model from other existing mouse medulloblastoma 
models (Figure 3-4A and B). Pten IHC staining showed that the vast majority of the 
tumor bulk was devoid of Pten with only endothelial cells retaining Pten (Figure 3-4C). 
The majority of the Nestin-CreERT2;Trp53loxP/loxP mice have to be euthanized for 
peripheral tumors probably due to leaky Cre activity outside of CNS (Figure 3-4D). 
Interestingly, the Nestin-CreERT2;PtenloxP/loxP;Trp53loxP/+ mice (5/8) developed glioma 
like malignancy in the cerebellum instead of medulloblastoma by 5-6 months old (see 
Appendix). Besides cerebellum, the dKO and Nestin-CreERT2;PtenloxP/loxP;Trp53loxP/+ 
mice also developed glioma like tumors in the forebrain (18/26, 5/8 respectively) and 
brain stem (5/26, 8/8) (see Appendix). 
 
 
Pten;Trp53 double knock-out medulloblastoma showed a growth pattern centering 
around blood vessels 
 
The dKO medulloblastomas were highly proliferative and showed predominant 
neuronal differentiation by IHC staining which confirms their identity as primitive 
neuroectodermal tumors (Figure 3-5). Most interestingly, these highly vascularized 
medulloblastomas often exhibited a growth pattern centering around blood vessels. The 
tumor cells showed a mature neuronal immunophenotype except those around blood 
vessels which expressed primitive markers including Nestin (Figure 3-5). At the edges of 
the tumors that were invading the non-tumor brain parenchyma, the Nestin+ and Ki67+ 
proliferative cells were often located immediately around blood vessels, which are 
reminiscent of the perivascular proliferative niches in the PtencKO cerebellum (Figure 3-3 
and Figure 3-5). These data suggest that the dKO medulloblastomas might initiate from 
the perivascular proliferative niches in the PtencKO cerebellum. 
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Figure 3-4. Co-deletion of Pten and Trp53 at birth resulted in medulloblastoma 
with unusual vascularization. 
(A and B) Representative H&E staining of medulloblastoma generated by co-deletion of 
Pten and Trp53 at birth shows pathology of classic medulloblastoma and high 
vascularization. (C) Pten IHC staining shows PtencKO;Trp53cKO dKO medulloblastoma 
cells are devoid of Pten except for the blood vessel. (D) Kaplan-Meier survival curves 
show PtencKO;Trp53cKO dKO mice with a median tumor onset of 63 days of age (red 
curve), PtencKO mice with a median morbidity age of 153 days of age (brown curve) and 
NestinCreERT2;Trp53loxP/loxP (Trp53cKO)with a median morbidity age of 135 days (green 
curve). PtencKO mice were euthanized due to macrocephaly and hydrocephaly. The 
majority of Trp53cKO were euthanized because of peripheral tumors. All genotypes were 
induced with TM at birth. Scale bar: B and C=50 μm. 
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Figure 3-5. Pten;Trp53 double knockout medulloblastoma showed a growth 
pattern centering around blood vessels. 
IHC staining as indicated of the medulloblastomas from dKO mice induced with TM at 
birth. Tuj1+ and NeuN+ IHC show the dKO medulloblastomas exhibited a neuronal 
immunophenotype except those cells around blood vessels. Nestin+ and Ki67+ IHC 
staining of the edges of the medulloblastomas show proliferative pregenitor cells were 
often located immediately around blood vessels that were invading the non-tumor brain 
parenchyma. Scale bar: 50 μm. 
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Pten;Trp53 double knock-out medulloblastoma spontaneously lost chromosome 7, 
13 and 16 
 
Tumorigenesis is considered a multi-step process involving initiation, promotion 
and progression. To understand what other secondary genetic alterations in addition to 
the initiating Pten and Trp53 mutations might be involved in the medulloblastoma 
formation, we did aCGH comparing genomic DNA from the tumors and reference 
genomic DNA from liver and spleen. We identified 3 most recurrent and consistent 
genomic abnormalities in tumor samples. All of the 18 medulloblastomas showed loss of 
chromosome 13 on which Ptch1 is located (Figure 3-6). In addition, 5 of the tumors had 
focal homozygous deletion of the BAC probe encompassing Ptch1. Thirteen and eighteen 
out of the 18 medulloblastomas also showed loss of the entire or part of chromosome 7 
and 16 respectively (Figure 3-6). No recurrent focal homozygous deletion on 
chromosome 7 or 16 could be found. Interestingly, two of the cerebellar non-
medulloblastoma tumors included in this aCGH analysis displayed a completely different 
landscape of genomic alterations than the medulloblastoma samples and failed to show 
loss of chromosomes 7 or 13 (Figure 3-6). 
 
 
Spontaneous deletion and mutation of Ptch1 occurred in Pten;Trp53 double knock-
out medulloblastomas 
 
To further investigate whether Ptch1 was the target gene of the genomic alteration 
on chromosome 13, we performed FISH analysis and detected loss of at least one allele 
of Ptch1 in two medulloblastoma samples used for aCGH analysis (Figure 3-7A). Real-
time PCR assay on the medulloblastoma genomic DNA further confirmed the copy 
number loss of Ptch1 in both tumor samples (Figure 3-7B). We also performed RT-PCR 
and direct sequencing to analyze Ptch1 mRNA and found mutations of Ptch1 in another 
two medulloblastomas samples used for aCGH analysis (Figure 3-7C). These data 
support the hypothesis that Ptch1 is the tumor suppressor gene on chromosome 13 that 
was selectively inactivated in dKO medulloblastoma by loss of heterozygosity. 
 
 
Discussion 
 
In this study, we used an inducible Nestin promoter driven Cre and deleted Pten 
in a wide-spectrum of the progenitors in cerebellum at birth when the brain is still 
undergoing active development. We recapitulated the phenotyes of neuronal hypertrophy 
and ectopic positioning found in previous studies and confirmed that Pten regulates 
neuronal size and positioning (Backman et al. 2001; Kwon et al. 2001; Fraser et al. 
2004). The more severe phenotypes of cerebellar disorganization and hypertrophy 
compared to previous studies might be because of the more potent and ubiquitous Cre 
activity in neural stem/progenitor cells driven by the Nestin promoter than by the Gfap 
promoter used previously. An unexpected finding in this study is that we revealed a novel 
perivascular proliferative progenitor niche in the cerebellum by deletion of Pten at birth 
which has never been found in any other studies. This suggests the presence of an  
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Figure 3-6. Pten;Trp53 double knockout medulloblastoma spontaneously lost 
chromosome 7, 13 and 16. 
(A) aCGH heat map of cerebellar tumors from Pten;Trp53 dKO mice induced with TM at 
birth. Each column represents one tumor sample. Numbers on the right indicate the 
chromosomes. The green color indicates copy number loss whereas red indicates copy 
number gain. All medulloblastoms (the two samples indicated by arrows were from non-
medulloblastoma samples) had loss of chromosome 7, 13 and 16 as highlighted in red.  
(B) aCGH analysis of chromosome 13 from one representative medulloblastoma sample 
shows hemizygous deletion of whole chromosome 13 and homozygous deletion at one 
BAC probe containing Ptch1 as indicated by an arrow.  
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Figure 3-7. Spontaneous deletion and mutation of Ptch1 in Pten;Trp53 double 
knockout medulloblastoma. 
(A) FISH analysis of a representative Pten;Trp53 dKO medulloblastoma sample. Red dot 
is a BAC probe located on one end of chromosome 13 outside of Ptch1 and green dot is a 
BAC probe containing Ptch1. (B) Quantitative real-time PCR analysis of Ptch1 on 
genomic DNA from dKO medulloblastomas. (C) Sequencing of cDNA synthesized from 
Ptch1 mRNA of 2 dKO medulloblastomas. Red boxes indicate the mutations by 
comparing reference wild-type sequence (Ref.) with medulloblastoma sequences  
(Tumor). 
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unknown perivascular germinal niche in the developing cerebellum that is normally 
regulated by Pten but regresses upon completion of development, because we could not 
see the niche anymore when deleting Pten in adulthood (data not shown). Alternatively, 
Pten deletion may have perturbed normal development and resulted in a perivascular 
germinal niche that does not normally exist. Our study is consistent with the previous 
study that identified neural stem cells in the murine postnatal cerebellum (Lee et al. 2005) 
and suggests that the neural stem cells in the cerebellum are probably localized in a 
vascular niche. This is consistent with the finding that the SVZ neural stem cells also 
reside in a vascular niche (Mirzadeh et al. 2008; Shen et al. 2008; Tavazoie et al. 2008). 
We tried to grow neurospheres from both wild-type and PtencKO P21 cerebella but did not 
get consistent results (data not shown). Our study also underlines the importance of Pten 
regulation in the neural stem/progenitor cells in the cerebellum indicating Pten is required 
for silencing or withdrawing the neural stem cells upon completion of development under 
physiological conditions. Our results are consistent with the finding that Pten negatively 
regulate proliferation and self-renewal of embryonic neural stem cells (Groszer et al. 
2001; Groszer et al. 2006) and is novel in that Pten loss caused spatially and temporally 
ectopic perivascular progenitor niches. 
 
The cerebellar perivascular hyperplasia, however, did not show progressive 
expansion up to 10 months of age and was never found to be transformed into full-blown 
tumor masses. This is consistent with our finding in Chapter 2 that Pten deletion is not 
sufficient to initiate tumorigenesis in neural stem/progenitor cells in the fore-brain and is 
in contrast to Pten function in other stem cells. For instance, in hemopoeitic stem cells, 
inactivation of Pten causes short-term expansion, but long-term decline and eventual 
leukemomogenesis (Yilmaz et al. 2006; Zhang et al. 2006) indicating a tissue-specific 
stem cell regulation by Pten. Activation of oncogenic signals such as c-Myc, E1A and 
Ras could not only promote proliferation and growth, but also induce cell cycle arrest and 
cell death (Askew et al. 1991; Lowe and Ruley 1993; Serrano et al. 1997) constraining 
tumorigenesis. Pten deficiency, a strong oncogenic stress, has been shown to induce p53, 
p16Ink4a or p19Arf and cause cellular senescence in prostate and hematopoietic cells (Chen 
et al. 2005; Lee et al. 2011). This might account for the limited cerebellar perivascular 
hyperplasia observed in this study. So we deleted Trp53, another common mutated tumor 
suppressor in human brain tumors in addition to deletion of Pten, which indeed resulted 
in medulloblastoma. This corresponds to recent large-scale human medulloblastoma 
sequencing data showing that PTEN and TP53 mutations occured simultaneously 
(Parsons et al. 2011). Therefore inactivation of PTEN and TP53 might also synergize in 
generating human medulloblastoma. 
 
The Pten and Trp53 dKO medulloblastoma in this study has very unique features 
that distinguish it from other mouse medulloblastoma models (Wetmore et al. 2000; Lee 
and McKinnon 2002; Zindy et al. 2003). Firstly, our medulloblastoma is highly 
vascularized manifesting as high-density of capillaries, extensive arborization and 
glomeruloid structures. This difference could be explained by the Pten inactivation in our 
medulloblastoma model and consequent PI3K pathway activation which have been 
shown to increase tumor angiogenesis through induction of VEGF or HIF1 in various 
tumor types (Giri and Ittmann 1999; Jiang et al. 2000; Zhong et al. 2000; Wen et al. 
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2001). In supporting this idea, one recent study demonstrates that loss of one copy of 
Pten promoted tumorigenesis and increased angiogenesis in a mouse medulloblastoma 
driven by over-expression of SmoA1 (Castellino et al. 2010). In addition, the potential 
perivascular origin of intrinsically angiogenic cells for this medulloblastoma might also 
account for its extensive vascularization. Secondly, our medulloblastoma is special in that 
it grows exclusively around blood vessels and show strong neuronal differentiation of 
cells not adjacent to blood vessels. This illustrates a lineage hierarchy of cancer cells in 
which medulloblastoma cancer stem/progenitor cells maintain themselves in a 
perivascular niche and start to differentiate when migrating out from the niche. This is 
consistent with a previous study showing the perivascular Nestin-expressing tumor cells 
were responsible for the recurrence of Ptch1 and Pten dKO medulloblastoma after 
irradiation (Hambardzumyan et al. 2008). The extensive neuronal differentiation of our 
Pten null medulloblastoma in contrast to the medulloblastoma models with intact Pten 
which show less neuronal differentiation underscores the role of Pten inactivation and 
PI3K activation in promoting neuronal lineage differentiation of medulloblastoma cells. 
This is supported by two other medulloblastoma models with extensive nodularity of 
neuronal differentiation in which Pten is inactivated (Hambardzumyan et al. 2008; 
Castellino et al. 2010). 
 
Human medulloblastoma is a heterogeneous disease that can be classified into 
several molecular subgroups based on genomic and expression profiles, one of which is 
enriched for mutations in sonic hedgehog (SHH) pathway (Thompson et al. 2006; Kool et 
al. 2008; Northcott et al. 2010; Cho et al. 2011). Mouse models of spontaneous 
medulloblastoma seem to over-represent the SHH subgroup of human disease in that the 
majority of mouse medulloblastomas harbor Ptch1 mutation (Wetmore et al. 2000; Zindy 
et al. 2007; Frappart et al. 2009) especially when involving Trp53 mutation. Our Pten and 
Trp53 dKO medulloblastoma also spontaneously developed Ptch1 mutations as well as 
other genomic abnormalities. One hundred percent penetrance of medulloblastoma and 
Ptch1 mutation indicates strong cooperation between PI3K, P53 and SHH pathways and 
potent selection pressure for Ptch1 inactivation in murine medulloblastoma genesis. Our 
tumor model is also very relevant to human disease given the recent sequencing data 
show PTEN mutation occurs exclusively together with either TP53 or PTCH1 mutations 
in all the medulloblastoma samples harboring PTEN mutation (Parsons et al. 2011). 
Although the subtype of SHH medulloblastomas are shown to be able to arise from the 
EGL (Schuller et al. 2008; Yang et al. 2008), our study suggests a potential new cell of 
origin for this subgroup.  
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CHAPTER 4.    GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
 
Pten and Postnatal Brain Development 
 
 
Pten and postnatal neurogenesis 
 
Postnatal brain development involves neurogenesis and gliogenesis as well as 
other processes such as angiogenesis. Postnatal neurogenesis mainly happens in three 
brain regions: the SVZ-RMS-OB, cerebellum and dentate gyrus. The present study 
showed that loss of Pten cause ectopic neuronal differention in both the SVZ-RMS-OB 
and cerebellum suggesting a unified Pten function in neurogenesis in different 
compartments of brain. However, Pten loss also showed region-specific phenotypes: the 
expansion is more dramatic on ventral and dorsal parts of the SVZ but less severe in the 
middle part which might be explained by the heterogeneity of the neural stem cells in the 
SVZ (Merkle et al. 2007). 
 
Neural stem cells in the SVZ reside in a niche with highly organized architecture 
in which they contact the ventricle with apical processes and blood vessels with basal 
processes (Mirzadeh et al. 2008; Shen et al. 2008; Tavazoie et al. 2008). In the expanded 
PtencKO SVZ, this specialized organization seems to be disrupted in that the proliferative 
progenitor cells are intermingled with differentiated neurons and sometimes located on 
the edge of the expansion away from the ventricle. Surprisingly, this altered architecture 
did not interfere with neurogenesis, given that no substantial changes in proliferation or 
apoptosis and no signs of an exhausted pool of neural stem cell were detected. In-depth 
analysis of the PtencKO SVZ by immunostaining or electron microscopy could provide 
specific insights into the relationship of neural stem cells to the ventricle and blood 
vessels in an altered niche. 
 
The present study shows deletion of Pten in neuroblasts caused ectopic 
differentiation without disrupting directional migration. This suggests the migration 
defect of Pten null neuroblasts is secondary to a premature differentiation in which 
programmed differentiation was accelerated and neuroblasts lost their migration 
capability before they reached their normal destination. Future experiments need to be 
done looking for direct evidence of precocious differentiation, for instance, by comparing 
wild-type and PtencKO neuroblasts at several timepoints after acute Pten deletion to see 
whether the differentiation program in PtencKO cells is expedited by examining temporal 
differentiation markers. Our rapamycin treatment experiment showed that the premature 
differentiation of PtencKO is dependent on mTorc1. Future study needs to address whether 
terminal differentiation of wild-type neuroblasts is also dependent on mTorc1 by 
knocking out mTorc1 components. We could not address this by rapamycin treatment 
because rapamycin differentially inhibits downstream signaling of mTorc1 (Choo et al. 
2008; Dowling et al. 2010) and has inconsistent penetration and inhibition in different 
compartments of brain which often results in incomplete inhibition. However, one 
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potential pitfall is that complete abolishion of mTorc1 activity might be incompatible 
with cell survival.  
 
One interesting phenomenon is that ectopic differentiated Pten-null neurons were 
distributed throughout the SVZ-RMS-OB indicating that PtencKO neuroblasts terminated 
their migration at different places. The possible reasons for this could be firstly that 
neuroblasts are born and start their migration at different regions of the SVZ. Secondly, 
deletion of Pten may have a stochastic effect on the termination of neuroblast migration. 
So it is possible mTorc1 signaling is not activated yet in the PtencKO neuroblasts 
maintaining directional migration at the timepoint of observation because the activation 
of mTorc1 pathway is determined by Pten status as well as other unknown factors. For 
instance, engagement of ligands (external cues) with tyrosine kinase receptors on the 
membrane is likely needed in the PtencKO neuroblast for full activation of PI3K-Akt-
mTorc1 pathway but might not be readily available to every neuroblast at a given 
timepoint. This might actually be a reflection of how neuroblasts terminate their 
migration naturally because in the wild-type brain migrating neuroblasts could stop 
anywhere throughout the whole OB layers. Future experiments could examine the status 
of mTorc1 signaling in the PtencKO neuroblasts that still maintain directional migration by 
means of, for instance, double labeling of EYFP and p-S6. Thirdly, migrating neuroblasts 
are a heterogeneous population (Merkle et al. 2007) that might respond to loss of Pten 
differentially. This is not likely the reason, however, because Pten null neurons were 
found to be in all of the OB layers that the neuroblasts normally integrate into. Since the 
neuroblasts give rise to multiple types of interneurons in the OB (Ihrie and Alvarez-
Buylla 2008), specific markers including TH, calbindin and calretinin for these 
interneurons could be used to examine if any of the interneuron subtype is more 
susceptible to Pten loss. 
 
 
Pten and postnatal gliogenesis 
 
Unlike neurogenesis which mainly happens during the embryonic stage, 
gliogenesis including astrocytogenesis and oligodendrocytogenesis peaks postnatally 
(Sauvageot and Stiles 2002). Loss of Pten resulted in hypertrophy and hyper-proliferation 
of astrocytes when using a Cre deleting Pten in both neurons and astrocytes during 
embryonic development (Fraser et al. 2004). This effect also contributed to the expansion 
of the SVZ and hypertrophy of the whole brain observed in this study. In the expanded 
SVZ of PtencKO but not wild-type mice, there were many hypertrophic astrocytes 
intermingled with retained Dcx+ neuronal precursors and differentiated NeuN+ mature 
neurons (see Appendix). There were also a huge number of hypertrophic astrocytes 
throughout the brain when Pten was deleted with the Nestin-CreERT2 transgene at birth 
(data not shown). However, astrocyte hypertrophy or hyper-proliferation could not be 
detected when Pten was deleted in the developmentally mature brain (Chow et al. 2011). 
The discrepancy in these studies is likely because Pten was deleted at different 
developmental stages or in different types of cells indicating cell-type-specific or stage-
specific Pten functions in astrocytes. Future study needs to find out whether the 
hypertrophic astrocytes in the PtencKO SVZ are differentiated from Pten null neural 
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stem/precursor cells or whether they are reactive astrocytes due to a non-cell-autonomous 
effect of Pten loss. It is not clear if there is a specific cell context in which loss of Pten 
will cause a cell-autonomous hypertrophy and hyper-proliferation of astrocytes. 
Preliminary data show that there were far fewer hypertrophic astrocytes and very few 
EYFP+ astrocytes in the SVZ when Pten was deleted by Cre electroporation compared to 
by the inducible Nestin-CreERT2 transgene. This suggests the astrocytosis in the PtencKO 
SVZ is likely a non-cell-autonomous effect (data not shown).  
 
 
Remaining questions on Pten and development 
 
Other questions raised in this study are what is the relationship between cell 
migration and differentiation? Are these two processes inter-linked or independent? Our 
study suggests that migration and differentiation are coordinated with each other. 
However, to what extent are they inter-connected? Does interruption of one process 
necessarily affect the other process? How is the differentiation affected in the neuroblasts 
in which only the migration machinery, for instance, mutations in PAR6α, LIS1,  
NUDEL, CDK5 and DCX, is interrupted.  
 
Why is there a discrepancy regarding whether Pten is required for directional 
migration in both Dictyostelium and mammalian cells? Is the discrepancy due to a cell-
context dependent effect of Pten on directional migration or simply technical issues? 
 
What are the cues that tell the migrating neuroblasts to stop and differentiate in 
the OB? One of the candidates is reelin, a critical extracellular protein regulating 
neuronal positioning (D'Arcangelo et al. 1995). Reelin had been shown to be required for 
the detachment of migrating neuroblasts from the RMS into the OB (Hack et al. 2002) 
and be able to activate PI3K-Akt-mTor pathway regulating dendritic growth (Jossin and 
Goffinet 2007). Disruption of ApoER2/VLDL, the receptors for reelin and Dab1, the 
downstream adapter protein (Andrade et al. 2007) showed a similar SVZ expansion 
associated with premature termination of tangential migration. 
 
 
Pten and Brain Tumorigenesis 
 
 
Cooperativity between Pten and other tumor suppressors 
 
Neural stem/progenitor cells are one of the largest proliferative populations in the 
brain throughout life and are hypothesized as cells of origin for brain tumors (Sanai et al. 
2005). In this study, deletion of Pten in the neural stem/progenitor cells in the SVZ of 
adult mice resulted in a dramatic expansion of the SVZ and RMS mainly due to early 
termination and ectopic differentiation with no progressive hyperplasia or malignant 
tumor formation. Similarly, the deletion of Pten in neural stem/progenitor cells in the 
developing postnatal brain only caused a very restricted hyper-proliferation around blood 
vessels in the cerebellum but not full-blown malignant tumor. These data indicate that 
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Pten loss of function alone is not sufficient for malignant transformation of the neural 
stem/progenitor cells in the absence of other gene mutations. This is consistent with 
patient data that although PTEN mutation is commonly found in 15-40% of GBMs, it 
rarely occurs in the low-grade gliomas (Ohgaki and Kleihues 2009). This could be due to 
the cell cycle arrest, senescence or apoptosis induced by Pten loss sensed by cells as an 
oncogenic stress similar to Ras and c-Myc activation mutations. Future studies need to 
address whether Pten deletion can indeed induce p53, p16Ink4a or p19Arf in the neural 
stem/progenitor cells whose tumor suppression had been shown to restrain tumor 
formation in other cell types (Chen et al. 2005; Lee et al. 2011). Neverthless, we are able 
to generate high-grade astrocytomas arising from the SVZ when co-deleting Pten and 
Trp53 in adult brain (see Appendix). In the developing brain, we could generate high-
grade gliomas as well as medulloblastomas in Nestin-CreERT2;PtenloxP/loxP;Trp53loxP/loxP 
mice, or highly infiltrative gliomas in Nestin-CreERT2;PtenloxP/loxP;Trp53loxP/wt mice (see 
Appendix). However, co-deletion of Pten and Cdkn2a, another commonly mutated gene 
locus in human gliomas encoding p16Ink4a and p19Arf, is not effective in generating any 
brain tumor in either mature or developing brains (data not shown). This indicates 
different cooperativities between Pten and other tumor suppressor pathways and tissue-
specific cooperativity between Pten and p16Ink4a or p19Arf pathways. 
 
 
Unified function of Pten in neurogenesis and medulloblastoma genesis? 
 
One striking similarity between PtencKO neuroblast in the SVZ and Pten;Trp53 
dKO medulloblastoma cell is that both of them had extensive neuronal differentiation. If 
we envision medulloblastoma genesis as a perturbed uncontrollable neurogenesis, this 
suggests Pten might have a similar role in normal neurogenesis and medulloblastoma 
genesis, that is to negatively regulate self-renewal and proliferation of neural or cancer 
stem cells and to keep the committed neuronal progenitors, either normal or cancerous, in 
an undifferentiated status. If this is true, does Pten have a similar role in the genesis of 
other brain tumor? 
 
 
Why is the perivascular niche only seen in the cerebellum? 
 
Even though the Nestin-CreERT2 targeted neural stem/progenitor cells throughout 
the developing brain, we only observed perivascular proliferative lesions in the 
cerebellum when deleting Pten at birth. There are multiple possibilities to explain this 
finding. Firstly, cerebellum lags behind other parts of brain during development which 
might provide a permissive environment for maintaining the perivascular niche. 
Secondly, there might be more primitive stem/progenitors only present during early 
development which had receded in regions other than cerebellum by birth. Supporting 
this idea, we saw less or no perivascular proliferative lesions when deleting Pten at later 
postnatal days. Thirdly, it is possible Nestin-CreERT2 target certain cell types only in the 
cerebellum. Future study needs to carefully compare the difference in the cell types 
targeted by Cre in different parts of the brain. 
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Cells of origin of brain tumors 
 
Different brain tumors might arise from different cells of origin. The Shh subtype 
of medulloblastoma might arise from the granule cell precursors of the cerebellar EGL 
whereas the Wnt subtype of medulloblastoma might develop from cells of dorsal brain 
stem (Gilbertson and Ellison 2008; Gibson et al. 2010). Although gliomas are 
hypothesized to originate from neural stem cells or glial progenitors, gliomas can arise 
from within or outside of proliferative niches in patients and mouse models (CBTRUS 
2010; Chow et al. 2011). In this study, tumors developed throughout the brain including 
the OB, cortex, SVZ, thalamus, hypothalamus, brain stem and cerebellum etc. This 
indicates that besides neural stem/progenitors in the germinal niches such as the SVZ, 
SGZ and EGL, cells outside of the proliferative niches could also serve as cells of origin. 
The other possibilities include NG2 cells (the oligodendrocyte progenitors present in both 
developing and mature brain)(Trotter et al. 2009) and cells associated with blood vessels 
Because these two cell types are found to be the most common proliferative cells outside 
of germinal niches (Dawson et al. 2003) if we think the proliferative cells are more 
susceptible to malignant transformation. Future study could introduce common genetic 
lesions found in patients into the specific cell types to determine their potential as cells of 
origin for brain tumors. In this study, we also found that the same genetic mutations 
could initiate different brain tumors, medulloblastoma or gliomas, developing from 
different brain regions, indicating that cells of origin also determine the histological types 
of brain tumors. 
 
 
Future directions for Pten;Trp53 double knock-out medulloblastoma 
 
Since the Pten;Trp53 double knock-out medulloblastoma exhibit a growth pattern 
centering around blood vessels, it will be interesting to determine whether they initiated 
from certain cells around blood vessels by checking early timepoints when the tumor just 
starts to grow. If so, what is the exact cell associated with the blood vessels that give rise 
to the medulloblastoma? Why do the tumor cells adjacent to the blood vessels show a 
primitive and less neuronal differentiation? What is the status of Shh pathway in the 
tumor cells immediately adjacent to the blood vessels compared to those moving away 
from the blood vessels? How does this medulloblastoma compare to human 
medulloblastoma harboring both PTEN and TP53 mutations, and to other existing mouse 
medulloblastoma models? 
 
 
Closing summary 
 
Overall, our study on Pten function in the context of both development and 
tumorigenesis show Pten regulates appropriate positioning of terminal neuronal 
differentiation by keeping neuroblasts in an undifferentiated state. Undifferentiated 
neuroblasts can still maintain the directional migration without Pten. Pten is required for 
preventing ectopic perivascular proliferative niche and medulloblastoma formation. 
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APPENDIX. SUPPLEMENTARY DATA 
 
 
 
 
 
Figure A-1. Increased number and size of astrocytes in the expanded PtencKO SVZ. 
Representative Gfap IHC staining of the SVZ from matched coronal brain sections of 
Nestin-CerERT2;PtenloxP/loxP (cKO) mice injected with TM on P30-32 and analyzed at 6 
months of age shows increase number and size of astrocytes in the expanded cKO SVZ. 
Bottom panels are the dorsal part of the SVZ. Scale bar: top panels=200 μm, bottom 
panels=50 μm. 
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Figure A-2. Deletion of Pten synergizes with Trp53 mutations to drive high-grade 
gliomas in adult brain arising from the SVZ. 
Nestin-CerERT2; PtenloxP/loxP;Trp53loxP/loxP (PtencKO;Trp53cKO), Nestin-CerERT2; 
Trp53loxP/loxP (Trp53cKO) and Nestin-CerERT2; PtenloxP/loxP (PtencKO) mice were induced 
with TM on P28-30. (A) Top panels: H&E staining of representative high-grade gliomas 
arising from the SVZ. Middle and bottom panels: representative H&E, Gfap, Pten and p-
Akt IHC staining of the high-grade gliomas from the SVZ show the tumor is Gfap+, 
Pten- and p-Akt+. Scale bar: 50 μm. (B) Kaplan-Meier survival curves show 
PtencKO;Trp53cKO mice with a median tumor onset of 180 days of age (red curve,) and 
Trp53cKO with a median morbidity age of 395 days (green curve). The PtencKO;Trp53cKO 
mice developed high-grade gliomas with 50% of penetrance as well as peripheral tumors 
The majority of Trp53cKO were euthanized because of peripheral tumors. 
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Figure A-3. Nestin-CreERT2;PtencKO;Tp53cHET mice developed highly infiltrative 
gliomas throughout brain. 
Nestin-CerERT2; PtenloxP/loxP;Trp53loxP/loxP (PtencKO;Trp53cKO), Nestin-
CerERT2;PtenloxP/loxP; Trp53loxP/wt (PtencKO;Trp53cHET) and Nestin-CerERT2; PtenloxP/loxP 
(PtencKO) were induced with TM on P0-1. (A) Kaplan-Meier survival curves show 
PtencKO;Trp53cHET mice with a median survival of 142 days of age (green curve) 
compared to 63 days for PtencKO;Trp53cKO mice (red curve which developed 
medulloblatomas) and 153 days for PtencKO mice (brown curve which were euthanized 
due to macrocephaly and hydrocephaly) (see also Chapter 3). (B) PtencKO;Trp53cHET mice 
developed highly infiltrative gliomas throughout brain. White boxes indicate the regions 
of interest shown in Figure A-4 with high magnification. 1: brain stem; 2: corpus 
callosum and cortex; 3: thalamus; 4: cerebellum; 5: SVZ. 
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Figure A-4. Highly infiltrative gliomas developed in Nestin-CreERT2;PtencKO; 
Tp53cHET mice. 
Representative H&E and Ki67 IHC staining of infiltrative gliomas developed in the 
regions shown in Figure A-3 from Nestin-CerERT2;PtenloxP/loxP; Trp53loxP/wt 
(PtencKO;Trp53cHET) mice induced with TM on P0-1. Scale bar: 50 μm. 
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Supplementary movie A-1. WT mice. 
 
 
Supplementary movie A-2. PtencKO mice. 
 
 
A Cre expression construct was transfected by in vivo electroporation at P2 into 
the SVZ of WT or Ptenflox/flox (cKO) mice carrying a ROSA-lox-STOP-lox-EYFP allele. 
Acute brain slices were prepared at P19-20, and cells in which Cre-mediated 
recombination occurred were visualized by EYFP reporter expression using two-photon 
microscopy. Images were captured every 5 minutes for 2.5 hours, and are presented in a 
movie of 4 seconds. Movies show the z-stack projections of 20 consecutive optical planes 
of section. 
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